Document:

Registration Rights Agreement

 Exhibit 4.1 
  

REGISTRATION RIGHTS AGREEMENT 
  
 Dated as of April 12, 2005 
  
 between 
  
 GREATER BAY BANCORP, 
  
 AND 
  
 KEEFE BRUYETTE & WOODS,
INC. 
  
 as the Initial Purchaser 

 REGISTRATION RIGHTS AGREEMENT 
  
 REGISTRATION RIGHTS AGREEMENT (the “Agreement”) dated as of April 12, 2005 between Greater Bay Bancorp, a
California corporation (the “Company”) and Keefe Bruyette & Woods, Inc. (the “Initial Purchaser”). 
  
 This Agreement is made pursuant to the Purchase Agreement, dated April 12, 2005, between the Company and the Initial Purchaser (the “Purchase
Agreement”), which provides for the sale by the Company to the Initial Purchaser of $150,000,000 aggregate principal amount of the Company’s 5.125% Senior Notes due 2010 (the “Notes”). In order to induce the Initial Purchaser to
enter into the Purchase Agreement and in satisfaction of a condition to the Initial Purchaser’s obligations thereunder, the Company has agreed to provide to the Initial Purchaser and its direct and indirect transferees and assigns the
registration rights set forth in this Agreement. The execution and delivery of this Agreement is a condition to the closing under the Purchase Agreement. 
  
 In consideration of the foregoing, the parties hereto agree as follows: 
  
 1. Definitions. As used in this Agreement, the following capitalized defined terms shall have the following meanings:

  
 “1933 Act” shall mean the
Securities Act of 1933, as amended from time to time, and the rules and regulations of the SEC promulgated thereunder. 
  
 “1934 Act” shall mean the Securities Exchange Act of 1934, as amended from time to time, and the rules and regulations of the
SEC promulgated thereunder. 
  
 “Additional
Interest” shall have the meaning set forth in Section 2(e) hereof. 
  
 “Applicable Period” shall have the meaning set forth in Section 3(f)(B) hereof. 
  
 “Closing Time” shall mean April 15, 2005. 
  
 “Depositary” shall mean The Depository Trust Company, or any other depositary appointed by the
Company, including any agent thereof; provided, however, that any such depositary must at all times have an address in the Borough of Manhattan, The City of New York. 
  
 “Event Date” shall have the meaning set forth in Section 2(e) hereof. 
  
 “Exchange Offer” shall mean the exchange offer by
the Company of Exchange Securities for Registrable Securities pursuant to Section 2(a) hereof. 

 “Exchange Offer Registration” shall mean a registration under the 1933 Act
effected pursuant to Section 2(a) hereof. 
  
 “Exchange Offer Registration Statement” shall mean an exchange offer registration statement of the Company on Form S-4 (or, if applicable, on another appropriate form) covering the Registrable Securities, and all amendments and
supplements to such registration statement, in each case including the Prospectus contained therein, all exhibits thereto and all material incorporated or deemed to be incorporated by reference therein. 
  
 “Exchange Securities” shall mean the securities,
issued by the Company under the Indenture with terms identical to the Notes (except that (i) interest thereon shall accrue from the last date to which interest has been paid or duly provided for on the Notes or, if no such interest has been paid or
duly provided for, from the Interest Accrual Date, (ii) provisions relating to an increase in the stated rate of interest thereon upon the occurrence of a Registration Default shall be eliminated, and (iii) the transfer restrictions, minimum
purchase requirements and legends relating to restrictions on ownership and transfer thereof as a result of the issuance of the Securities without registration under the 1933 Act shall be eliminated other than requiring transfers in multiples of
$1,000) to be offered to Holders of Registrable Securities in exchange for Registrable Securities pursuant to the Exchange Offer. 
  
 “Holders” shall mean (i) the Initial Purchaser, for so long as it owns any Registrable Securities, and each of its successors,
assigns and direct and indirect transferees who become registered owners of Registrable Securities under the Indenture and (ii) each Participating Broker-Dealer that holds Exchange Securities for so long as such Participating Broker-Dealer is
required to deliver a prospectus meeting the requirements of the 1933 Act in connection with any resale of such Exchange Securities. 
  
 “Indenture” shall mean the Indenture, dated as of March 24, 2003, by and between the Company and Wilmington Trust Company, as
trustee, as the same may be further amended or supplemented from time to time in accordance with the terms thereof. 
  
 “Interest Accrual Date” means April 15, 2005. 
  
 “Initial Purchaser” shall have the meaning set forth in the preamble of this Agreement.

  
 “Majority Holders” shall mean the
Holders of a majority of the aggregate principal amount of Registrable Securities outstanding, excluding Exchange Securities referred to in clause (ii) of the definition of “Holders” above; provided that whenever the consent or approval of
Holders of a specified percentage of Registrable Securities or Exchange Securities is required hereunder, Registrable Securities and Exchange Securities held by the Company or any of its affiliates 
  

 2 

 (as such term is defined in Rule 405 under the 1933 Act) shall also be disregarded in determining whether
such consent or approval was given by the Holders of such required percentage. 
  
 “NASD” shall mean the National Association of Securities Dealers, Inc. 
  
 “Notes” shall have the meaning set for the in the
preamble to this Agreement. 
  
 “Notifying
Broker-Dealer” shall have the meaning set forth in Section 3(f) hereof. 
  
 “Participating Broker-Dealer” shall have the meaning set forth in Section 3(f) hereof. 
  
 “Person” shall mean an individual, partnership, joint venture, limited liability company, corporation, trust or unincorporated
organization, or a government or agency or political subdivision thereof. 
  
 “Private Exchange Securities” shall have the meaning set forth in Section 2(a) hereof. 
  
 “Private Exchange” shall have the meaning set forth in Section 2(a). 
  
 “Prospectus” shall mean the prospectus included in
a Registration Statement, including any preliminary prospectus, and any such prospectus as amended or supplemented by any prospectus supplement, including a prospectus supplement with respect to the terms of the offering of any portion of the
Registrable Securities covered by a Shelf Registration Statement, and by all other amendments and supplements to a prospectus, including post-effective amendments, and in each case including all material incorporated or deemed to be incorporated by
reference therein. 
  
 “Purchase
Agreement” shall have the meaning set forth in the preamble to this Agreement. 
  
 “Registrable Securities” shall mean the Notes; provided, however, that any Notes shall cease to be Registrable Securities when
(i) a Registration Statement with respect to such Notes shall have been declared effective under the 1933 Act and such Notes shall have been disposed of pursuant to such Registration Statement, (ii) such Notes, which are eligible to be sold without
restriction as contemplated by Rule 144, shall have been sold to the public pursuant to Rule 144 (or any similar provision then in force, but not Rule 144A) under the 1933 Act, (iii) such Notes shall have ceased to be outstanding, (iv) such Notes
have been exchanged for Exchange Securities which have been registered pursuant to the Exchange Offer Registration Statement upon consummation of the Exchange Offer unless, in the case of any Exchange Securities referred to in this clause (iv), such
Exchange Securities are held by Participating Broker-Dealers or otherwise 
  

 3 

 are not freely tradable without any limitations or restrictions under the 1933 Act (in which case such
Exchange Securities will be deemed to be Registrable Securities until the earlier of (A) expiration of the Applicable Period and (B) such time as such Exchange Securities are sold to a purchaser in whose hands such Exchange Securities are freely
tradeable without any limitations or restrictions under the 1933 Act) or (v) such Notes have been exchanged for Private Exchange Securities pursuant to this Agreement (in which case such Private Exchange Securities will be deemed to be Registrable
Securities until the earlier of (A) 210 days after the completion of the Exchange Offer and (B) such time as such Private Exchange Securities are sold to a purchaser in whose hands such Private Exchange Securities are freely tradeable without any
limitations or restrictions under the 1933 Act). 
  
 “Registration Default” shall have the meaning set forth in Section 2(e) hereof. 
  
 “Registration Expenses” shall mean any and all expenses incident to performance of or compliance by the Company with this
Agreement, including without limitation: (i) all SEC, stock exchange or NASD registration and filing fees; (ii) all fees and expenses incurred in connection with compliance with state or other securities or blue sky laws and compliance with the
rules of the NASD (including fees and disbursements of one counsel for all the underwriters or Holders as a group in connection with qualification of any of the Exchange Securities or Registrable Securities under state or other securities or blue
sky laws and any filing with and review by the NASD); (iii) all expenses of any Persons in preparing, printing and distributing any Registration Statement, any Prospectus, any amendments or supplements thereto, any underwriting agreements,
securities sales agreements, and certificates representing the Notes, Private Exchange Securities (if any) or Exchange Securities and other documents relating to the performance of and compliance with this Agreement; (iv) all rating agency fees; (v)
all fees and expenses incurred in connection with the listing, if any, of any of the Notes or Exchange Securities on any securities exchange or exchanges or on any quotation system; (vi) all fees and disbursements relating to the qualification of
the Indenture under applicable securities laws; (vii) the fees and disbursements of counsel for the Company and the fees and expenses of independent public accountants for the Company or for any other Person, business or assets whose financial
statements are included in any Registration Statement or Prospectus, including the expenses of any special audits or “cold comfort” letters required by or incident to such performance and compliance; (viii) the fees and expenses of the
Trustee, any registrar, any depositary, any paying agent, any escrow agent or any custodian, in each case including fees and disbursements of their respective counsel; (ix) the fees and expenses of the Initial Purchaser in connection with the
Exchange Offer, including the fees and disbursements of one counsel to the Initial Purchaser in connection therewith; and (x) in the case of an underwritten offering, any fees and disbursements of the underwriters customarily paid by issuers and
sellers of securities and the fees and expenses of any special experts retained by the Company in connection with any Registration Statement but excluding 
  

 4 

 (except as otherwise provided herein) fees and disbursements of counsel to the underwriters and the
Holders and underwriting discounts and commissions and transfer taxes, if any, relating to the sale or disposition of Registrable Securities by a Holder. 
  
 “Registration Statement” shall mean any registration statement of the Company relating to any offering of the Exchange
Securities or Registrable Securities pursuant to the provisions of this Agreement (including, without limitation, any Exchange Offer Registration Statement and any Shelf Registration Statement), and all amendments and supplements to any such
Registration Statement, including post-effective amendments, in each case including the Prospectus contained therein, all exhibits thereto and all material incorporated or deemed to be incorporated by reference therein. 
  
 “SEC” shall mean the Securities and Exchange
Commission or any successor thereto. 
  
 “Shelf Registration” shall mean a registration effected pursuant to Section 2(b) hereof. 
  
 “Shelf Registration Statement” shall mean a “shelf” registration statement of the Company pursuant to the provisions
of Section 2(b) of this Agreement which covers all of the Registrable Securities or Private Exchange Securities (if any), as the case may be, on an appropriate form under Rule 415 under the 1933 Act, or any similar rule that may be adopted by the
SEC, and all amendments and supplements to such registration statement, including post-effective amendments, in each case including the Prospectus contained therein, all exhibits thereto and all material incorporated or deemed to be incorporated by
reference therein. 
  
 “TIA” shall mean
the Trust Indenture Act of 1939, as amended from time to time, and the rules and regulations of the SEC promulgated thereunder. 
  
 “Trustee” shall mean the trustee with respect to the Notes, the Private Exchange Securities (if any) and the Exchange Securities
under the Indenture. 
  
 For purposes of this Agreement: (i) all
references in this Agreement to any Registration Statement, Prospectus or any amendment or supplement to any of the foregoing shall be deemed to include the copy filed with the SEC pursuant to its Electronic Data Gathering, Analysis and Retrieval
system (“EDGAR”); (ii) all references in this Agreement to financial statements and schedules and other information which is “contained,” “included,” “disclosed” or “stated” in any Registration
Statement or Prospectus (or other references of like import) shall be deemed to mean and include all such financial statements and schedules and other information which is incorporated or deemed to be incorporated by reference in such Registration
Statement or Prospectus, as the case may be; (iii) all references in this Agreement to amendments or supplements to any Registration Statement or Prospectus shall be deemed to mean and include the filing of any document under the 1934 Act which is
incorporated or deemed to be incorporated by reference in such Registration Statement or Prospectus, as the case may be; (iv) 
  

 5 

 all references in this Agreement to Rule 144, Rule 144A or Rule 405 under the 1933 Act, and all references to any
sections or subsections thereof or terms defined therein, shall in each case include any successor provisions thereto; and (v) all references in this Agreement to days (but not to business days) shall mean calendar days. 
  
 2. Registration Under the 1933 Act. 
  
 (a) Exchange Offer Registration. The Company shall (A) file with the SEC on
or prior to the 120th day after the Closing Time an Exchange Offer Registration Statement covering the offer by the Company to the Holders to exchange all of the Registrable Securities for a like aggregate principal amount of Exchange Securities,
(B) use its reasonable best efforts to cause such Exchange Offer Registration Statement to be declared effective by the SEC no later than the 180th day after the Closing Time, (C) use its reasonable best efforts to cause such Registration Statement
to remain effective until the closing of the Exchange Offer and (D) use its reasonable best efforts to consummate the Exchange Offer no later than 45 days after the effective date of the Exchange Offer Registration Statement. Upon the effectiveness
of the Exchange Offer Registration Statement, the Company shall promptly commence the Exchange Offer, it being the objective of such Exchange Offer to enable each Holder eligible and electing to exchange Registrable Securities for Exchange
Securities (provided that such Holder is not an affiliate of the Company within the meaning of Rule 405 under the 1933 Act, acquires the Exchange Securities in the ordinary course of such Holder’s business and has no arrangements or
understandings with any Person to participate in the Exchange Offer for the purpose of distributing such Exchange Securities) to trade such Exchange Securities from and after their receipt without any limitations or restrictions under the 1933 Act
or under the securities or blue sky laws of the states of the United States other than requiring transfers in multiples of $1,000. 
  
 In connection with the Exchange Offer, the Company shall: 
  
 (i) promptly mail to each Holder a copy of the Prospectus forming part of the Exchange Offer Registration Statement, together with an
appropriate letter of transmittal and related documents; 
  
 (ii) keep the Exchange Offer open for not less than 20 business days (or longer, if required by applicable law) after the date notice thereof is mailed to the Holders and, during the Exchange Offer, offer to all
Holders who are legally eligible to participate in the Exchange Offer the opportunity to exchange their Registrable Securities for Exchange Securities; 
  
 (iii) use the services of a depositary with an address in the Borough of Manhattan, The City of New York for the Exchange Offer;

  
 (iv) permit Holders to withdraw tendered
Registrable Securities at any time prior to the close of business, New York City time, on the last business day on which the Exchange Offer shall remain open, by sending to the institution specified in the Prospectus or the related letter of
transmittal or related documents a facsimile transmission or letter setting forth the name of such Holder, the principal amount of Registrable Securities delivered for exchange, and a statement that such Holder is withdrawing its election to have
such Registrable Securities exchanged; 
  

 6 

 (v) notify each Holder that any Registrable Security not tendered will remain outstanding
and continue to accrue interest, but will not retain any rights under this Agreement (except in the case of the Initial Purchaser and Participating Broker-Dealers as provided herein); and 
  
 (vi) otherwise comply in all material respects with all
applicable laws relating to the Exchange Offer. 
  
 If, at or
prior to the consummation of the Exchange Offer, the Initial Purchaser holds any Notes acquired by it and having the status of an unsold allotment in the initial distribution, the Company shall, upon the request of the Initial Purchaser,
simultaneously with the delivery of the Exchange Securities in the Exchange Offer, issue and deliver to the Initial Purchaser in exchange for such Notes a like principal amount of debt securities (the “Private Exchange”) of the Company
that are identical (except that such debt securities shall be subject to transfer restrictions and minimum purchase requirements, and shall bear a legend relating to restrictions on ownership and transfer, identical to those applicable to the Notes
as a result of the issuance thereof without registration under the 1933 Act and shall provide for the payment of Additional Interest) to the Exchange Securities (the “Private Exchange Securities”). The Company shall use its reasonable best
efforts to have the Private Exchange Securities bear the same CUSIP number as the Exchange Securities and, if unable to do so, the Company will, at such time as any Private Exchange Security may be sold publicly pursuant to Rule 144(k) under the
1933 Act, permit any such Private Exchange Security to be exchanged for a like principal amount of Exchange Securities. 
  
 The Exchange Securities and the Private Exchange Securities (if any) shall be issued under the Indenture, which shall be qualified under the TIA. The
Notes shall provide that the Exchange Securities issued in respect thereof, the Private Exchange Securities (if any) issued in respect thereof and the Notes shall vote and consent together on all matters as a single class and shall constitute a
single series of debt securities issued under the Indenture. 
  
 As soon as practicable after the close of the Exchange Offer and, if applicable, the Private Exchange, the Company shall: 
  
 (i) accept for exchange all Registrable Securities duly tendered and not validly withdrawn pursuant to the Private Exchange or the
Exchange Offer in accordance with the terms of the Exchange Offer Registration Statement and the letter of transmittal which is an exhibit thereto; 
  
 (ii) deliver, or cause to be delivered, to the Trustee for cancellation all Registrable Securities so accepted for exchange by the
Company; and 
  
 (iii) cause the Trustee promptly
to authenticate and deliver Exchange Securities to each Holder of Registrable Securities so accepted for exchange equal in principal amount to the principal amount of the Registrable Securities of such Holder so accepted for exchange. 
  

 7 

 Interest on each Exchange Security and each Private Exchange Security (if any) will accrue from the last
date on which interest was paid or duly provided for on the Notes surrendered in exchange therefor or, if no interest has been paid or duly provided for on such Notes, from the Interest Accrual Date. The Exchange Offer shall not be subject to any
conditions, other than (i) that the Exchange Offer, or the making of any exchange by a Holder, does not violate any applicable law or any applicable interpretation of the staff of the SEC, (ii) that no action or proceeding shall have been instituted
or threatened in any court or by or before any governmental agency with respect to the Exchange Offer which, in the Company’s judgment, would reasonably be expected to impair the ability of the Company to proceed with the Exchange Offer, and
(iii) that the Holders tender the Registrable Securities to the Company in accordance with the Exchange Offer. Each Holder of Registrable Securities (other than Participating Broker-Dealers) who wishes to exchange such Registrable Securities for
Exchange Securities in the Exchange Offer will be required to represent that (i) it is not an affiliate (as defined in Rule 405 under the 1933 Act) of the Company, (ii) any Exchange Securities to be received by it will be acquired in the ordinary
course of business and (iii) it has no arrangement with any Person to participate in the distribution (within the meaning of the 1933 Act) of the Exchange Securities, and shall be required to make such other representations as may be reasonably
necessary under applicable SEC rules, regulations or interpretations to render the use of Form S-4 or another appropriate form under the 1933 Act available. To the extent permitted by law, the Company shall inform the Initial Purchaser of the names
and addresses of the Holders of Securities to whom the Exchange Offer is made and, to the extent such information is available to the Company, the names and addresses of the beneficial owners of such Securities, and the Initial Purchaser shall have
the right to contact such Holders and beneficial owners and otherwise facilitate the tender of Registrable Securities in the Exchange Offer. 
  
 (b) Shelf Registration. (i) If, because of any change in law or applicable interpretations thereof by the staff of the SEC, the Company is not permitted
to effect the Exchange Offer as contemplated by Section 2(a) hereof, or (ii) if for any other reason (A) the Exchange Offer Registration Statement is not declared effective within 180 days following the Closing Time or (B) the Exchange Offer is not
consummated within 45 days after effectiveness of the Exchange Offer Registration Statement (provided that if the Exchange Offer Registration Statement shall be declared effective after such 180-day period or if the Exchange Offer shall be
consummated after such 45-day period, then the Company’s obligations under this clause (ii) arising from the failure of the Exchange Offer Registration Statement to be declared effective within such 180-day period or the failure of the Exchange
Offer to be consummated within such 45-day period, respectively, shall terminate), or (iii) upon the request of the Initial Purchaser (unless the Initial Purchaser is holding Notes acquired directly from the Company) within 30 days following the
consummation of the Exchange Offer if the Initial Purchaser (A) is not eligible to participate in the Exchange Offer or (B) elects to participate in the Exchange Offer but does not receive Exchange Securities which are freely tradeable without any
limitations or restrictions under the 1933 Act, or (iv) upon the request of the Initial Purchaser within 90 days following the consummation of the Exchange Offer (provided that, in the case of this clause (iv), the Initial Purchaser shall hold
Registrable Securities (including, without limitation, Private Exchange Securities) from an initial allotment that it acquired directly from the Company), the Company shall, at its cost: 
  
 (A) as promptly as practicable, but no later than (a) the 180th day after the Closing Time or (b) the 75th
day after any such filing obligation arises, whichever is later, file with the SEC a Shelf Registration Statement relating to the offer and sale of the Registrable Securities by the Holders from time to time in accordance with the methods of
distribution elected by the Majority Holders of such Registrable Securities and set forth in such Shelf Registration Statement; 
  

 8 

 (B) use its reasonable best efforts to cause such Shelf Registration Statement to be
declared effective by the SEC as promptly as practicable, but in no event later than the 240th day after the Closing Time (or, in the case of a request by the Initial Purchaser pursuant to clause (iii) or (iv) above, within 120 days after such
request). In the event that the Company is required to file a Shelf Registration Statement pursuant to clause (iii) or (iv) above, the Company shall file and use its reasonable best efforts to have declared effective by the SEC both an Exchange
Offer Registration Statement pursuant to Section 2(a) with respect to all Registrable Securities and a Shelf Registration Statement (which may be a combined Registration Statement with the Exchange Offer Registration Statement) with respect to
offers and sales of Registrable Securities held by the Initial Purchaser; 
  
 (C) use its reasonable best efforts to keep the Shelf Registration Statement continuously effective, supplemented and amended as required, in order to permit the Prospectus forming part thereof to be usable by Holders
for a period of two years after the latest date on which any Securities are originally issued by the Company (subject to extension pursuant to the last paragraph of Section 3) (or, solely in the case of clause (iii) or (iv) above of this Section
2(b), 210 days after completion of the Exchange Offer) or, if earlier, when all of the Registrable Securities covered by such Shelf Registration Statement (i) have been sold pursuant to the Shelf Registration Statement in accordance with the
intended method of distribution thereunder, (ii) become eligible for resale pursuant to Rule 144(k) under the 1933 Act or (iii) cease to be Registrable Securities; and 
  
 (D) notwithstanding any other provisions hereof, use its best efforts to ensure that (i) any Shelf
Registration Statement and any amendment thereto and any Prospectus forming a part thereof and any supplements thereto comply in all material respects with the 1933 Act and the rules and regulations thereunder, (ii) any Shelf Registration Statement
and any amendment or supplement thereto does not, when it becomes effective, contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading and
(iii) any Prospectus forming part of any Shelf Registration Statement and any amendment or supplement to such Prospectus does not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the
statements therein, in the light of the circumstances under which they were made, not misleading. 
  
 The Company shall not permit any securities other than Registrable Securities to be included in the Shelf Registration Statement without the prior written
consent of the Initial 
  

 9 

 Purchaser. The Company further agrees, if necessary, to supplement or amend the Shelf Registration Statement if
reasonably requested by the Majority Holders with respect to information relating to the Holders and otherwise as required by Section 3(b) below, to use its reasonable best efforts to cause any such amendment to become effective and such Shelf
Registration Statement to become usable as soon as practicable thereafter and to furnish to the Holders of Registrable Securities copies of any such supplement or amendment promptly after its being used or filed with the SEC. 
  
 (c) Expenses. The Company shall pay all Registration Expenses in connection
with the registration pursuant to Section 2(a) and 2(b) hereof and, in the case of any Shelf Registration Statement, will reimburse the Holders or the Initial Purchaser for the fees and disbursements of one counsel designated in writing by the
Majority Holders (or, if a Shelf Registration Statement is filed solely pursuant to clause (iv) of the first paragraph of Section 2(b), designated by the Initial Purchaser) to act as counsel for the Holders of the Registrable Securities in
connection with a Shelf Registration. Each Holder shall pay all fees and disbursements of its counsel other than as set forth in the preceding sentence or in the definition of Registration Expenses and all underwriting discounts and commissions and
transfer taxes, if any, relating to the sale or disposition of such Holder’s Registrable Securities pursuant to a Shelf Registration Statement. 
  
 (d) Effective Registration Statement. 
  
 (i) The Company shall be deemed not to have used its reasonable best efforts to cause the Exchange Offer Registration Statement or any
Shelf Registration Statement, as the case may be, to become, or to remain, effective during the requisite periods set forth herein if the Company takes any action or fails to take action that could reasonably be expected to result in any such
Registration Statement not being declared effective or remaining effective or in the case of the Holders of Registrable Securities (including, under the circumstances contemplated by Section 3(f) hereof, Exchange Securities) covered thereby not
being able to exchange or offer and sell such Registrable Securities during that period unless (A) such action is required by applicable law or (B) such action is taken by the Company in good faith and for valid business reasons (but not including
avoidance of the Company’s obligations hereunder), including the acquisition or divestiture of assets or a material corporate transaction or event so long as the Company promptly complies with the notification requirements of Section 3(k)
hereof, if applicable. Nothing in this paragraph shall prevent the accrual of Additional Interest on any Registrable Securities. 
  
 (ii) An Exchange Offer Registration Statement pursuant to Section 2(a) hereof or a Shelf Registration Statement pursuant to Section 2(b)
hereof shall not be deemed to have become effective unless it has been declared effective by the SEC; provided, however, that if, after such Registration Statement has been declared effective, the offering of Registrable Securities pursuant to a
Registration Statement is interfered with by any stop order, injunction or other order or requirement of the SEC or any other governmental agency or court, such Registration Statement shall be deemed not to have been effective during the period of
such interference until the offering of Registrable Securities pursuant to such Registration Statement may legally resume. 
  

 10 

 (iii) During any 365 day period, the Company may, by notice as described in Section 3(e)
hereof, suspend the availability of a Shelf Registration Statement (and, if the Exchange Offer Registration Statement is being used in connection with the resale of Exchange Securities by Participating Broker Dealers as contemplated by Section 3(f),
the Exchange Offer Registration Statement) and the use of the related Prospectus for up to 45 consecutive days each, but no more than an aggregate of 90 days during any 365 day period, upon the happening of any event or the discovery of any fact or
the taking of any action referred to in Section 3(e)(vi), but subject to compliance by the Company with its obligations under the last paragraph of Section 3. 
  

(e) Increase in Interest Rate. In the event that: 
  
 (i) the Exchange Offer Registration Statement is not filed with the SEC on or prior to the 120th day following the Closing Time, or

  
 (ii) the Exchange Offer Registration
Statement is not declared effective by the SEC on or prior to the 180th day following the Closing Time, or 
  
 (iii) the Exchange Offer is not consummated on or prior to the 45th day following the effective date of the Exchange Offer Registration
Statement, or 
  
 (iv) if required, a Shelf
Registration Statement is not filed with the SEC on or prior to (A) the 180th day following the Closing Time or (B) the 75th day after the filing obligation arises, whichever is later, or 
  
 (v) if required, a Shelf Registration Statement is not
declared effective on or prior to the 240th day following the Closing Time (or, if a Shelf Registration Statement is required to be filed upon the request of the Initial Purchaser, within 120 days after such request), or 
  
 (vi) a Shelf Registration Statement is declared effective by
the SEC but such Shelf Registration Statement ceases to be effective or such Shelf Registration Statement or the Prospectus included therein ceases to be usable in connection with resales of Registrable Securities for any reason and (A) the
aggregate number of days in any consecutive 365-day period for which the Shelf Registration Statement or such Prospectus shall not be effective or usable exceeds 90 days, (B) the Shelf Registration Statement or such Prospectus shall not be effective
or usable for more than two periods (regardless of duration) in any consecutive 365-day period or (C) the Shelf Registration Statement or such Prospectus shall not be effective or usable for a period of more than 45 consecutive days, or 

 
 (vii) the Exchange Offer Registration Statement is
declared effective by the SEC but, if the Exchange Offer Registration Statement is being used in 
  

 11 

 connection with the resale of Exchange Securities as contemplated by Section 3(f)(B) of this Agreement,
the Exchange Offer Registration Statement ceases to be effective or the Exchange Offer Registration Statement or the Prospectus included therein ceases to be usable in connection with resales of Exchange Securities for any reason during the
Applicable Period (as such period may be extended pursuant to the last paragraph of Section 3 of this Agreement) and (A) the aggregate number of days in any consecutive 365-day period for which the Exchange Offer Registration Statement or such
Prospectus shall not be effective or usable exceeds 90 days, (B) the Exchange Offer Registration Statement or such Prospectus shall not be effective or usable for more than two periods (regardless of duration) in any consecutive 365-day period or
(C) the Exchange Offer Registration Statement or the Prospectus shall not be effective or usable for a period of more than 45 consecutive days, (each of the events referred to in clauses (i) through (vii) above being hereinafter called a
“Registration Default”), the per annum interest rate borne by the Registrable Securities shall be increased (“Additional Interest”) by one-quarter of one percent (0.25%) per annum immediately following such 120-day period in the
case of clause (i) above, immediately following such 180-day period in the case of clause (ii) above, immediately following such 45-day period in the case of clause (iii) above, immediately following any such 180-day period or 75-day period,
whichever ends later, in the case of clause (iv) above, immediately following any such 240-day period or 120-day period, whichever ends first, in the case of clause (v) above, immediately following the 90th day in any consecutive 365-day period, as
of the first day of the third period in any consecutive 365-day period or immediately following the 45th consecutive day, whichever occurs first, that a Shelf Registration Statement shall not be effective or a Shelf Registration Statement or the
Prospectus included therein shall not be usable as contemplated by clause (vi) above, or immediately following the 90th day in any consecutive 365-day period, as of the first day of the third period in any consecutive 365-day period or immediately
following the 45th consecutive day, whichever occurs first, that the Exchange Offer Registration Statement shall not be effective or the Exchange Offer Registration Statement or the Prospectus included therein shall not be usable as contemplated by
clause (vii) above; provided that the aggregate increase in such annual interest rate under this Section 2(e) may in no event exceed one-quarter of one percent (0.25%) per annum; further provided that the aggregate increase in such annual interest
rate may in no event be in excess of the rate permissible under applicable law. Upon the filing of the Exchange Offer Registration Statement after the 120-day period described in clause (i) above, the effectiveness of the Exchange Offer Registration
Statement after the 180-day period described in clause (ii) above, the consummation of the Exchange Offer after the 45-day period described in clause (iii) above, the filing of the Shelf Registration Statement after the 180-day period or 75-day
period day, as the case may be, described in clause (iv) above, the effectiveness of a Shelf Registration Statement after the 240-day period or 120-day period, as the case may be, described in clause (v) above, the Shelf Registration Statement once
again being effective or the Shelf Registration Statement and the Prospectus included therein 
  

 12 

 becoming usable in connection with resales of Registrable Securities, as the case may be, in the case of
clause (vi) above, or the Exchange Offer Registration Statement once again becoming effective or the Exchange Offer Registration Statement and the Prospectus included therein becoming usable in connection with resales of Exchange Securities, as the
case may be, in the case of clause (vii) thereof, the interest rate borne by the Securities from the date of such filing, effectiveness, consummation or resumption of effectiveness or usability, as the case may be, shall be reduced to the original
interest rate so long as no other Registration Default shall have occurred and shall be continuing at such time and the Company is otherwise in compliance with this paragraph; provided, however, that, if after any such reduction in interest rate,
one or more Registration Defaults shall again occur, the interest rate shall again be increased pursuant to the foregoing provisions. 
  
 The Company shall notify the Trustee within three business days after each and every date on which an event occurs or fails to occur in respect of which
Additional Interest is required to be paid (an “Event Date”). Additional Interest shall be paid by depositing with the Trustee, in trust, for the benefit of the Holders of Registrable Securities, on or before the applicable semiannual
interest payment date, immediately available funds in sums sufficient to pay the Additional Interest then due. The Additional Interest due shall be payable on each interest payment date to the record Holder of Securities entitled to receive the
interest payment to be paid on such date as set forth in the Indenture. Each obligation to pay Additional Interest shall be deemed to accrue from and including the day following the applicable Event Date. Anything herein to the contrary
notwithstanding, any Holder who was, at the time the Exchange Offer was pending and consummated, eligible to exchange, and did not validly tender, its Notes for Exchange Securities in the Exchange Offer will not be entitled to receive any Additional
Interest. For purposes of clarity, it is hereby acknowledged and agreed that, under current interpretations of law by the SEC, the Initial Purchaser is not eligible to participate in the Exchange Offer if it holds unsold allotments of Notes acquired
from the Company. 
  
 (f) Specific Enforcement. Without limiting
the remedies available to the Initial Purchaser and the Holders, the Company acknowledges that any failure by the Company to comply with its obligations under Sections 2(a) through 2(d) hereof may result in material irreparable injury to the Initial
Purchaser, the Holders or the Participating Broker-Dealers for which there is no adequate remedy at law, that it will not be possible to measure damages for such injuries precisely and that, in the event of any such failure, the Initial Purchaser,
any Holder and any Participating Broker-Dealer may obtain such relief as may be required to specifically enforce the Company’s obligations under Sections 2(a) through 2(d) hereof. 
  
 3. Registration Procedures. In connection with the obligations of the Company with respect to the Registration Statements
pursuant to Sections 2(a) and 2(b) hereof, the Company shall: 
  
 (a) prepare and file with the SEC a Registration Statement or, if required, Registration Statements, within the time periods specified in Section 2, on the appropriate form under the 1933 Act, which form (i) shall be selected by the
Company, (ii) shall, in the case of a Shelf Registration Statement, be available for the sale of the Registrable Securities by the selling 
  

 13 

 Holders thereof and, in the case of an Exchange Offer, be available for the exchange of Registrable Securities and (iii)
shall comply as to form in all material respects with the requirements of the applicable form and include or incorporate by reference all financial statements required by the SEC to be filed therewith, and use its reasonable best efforts to cause
such Registration Statement to become effective (and, in the case of a Shelf Registration Statement, usable for resales) and remain effective in accordance with Section 2 hereof; 
  
 (b) prepare and file with the SEC such amendments and post-effective amendments to each Registration Statement as may be
necessary under applicable law to keep such Registration Statement effective for the applicable period; cause each Prospectus to be supplemented by any required prospectus supplement, and as so supplemented to be filed pursuant to Rule 424 under the
1933 Act; and comply with the provisions of the 1933 Act and the 1934 Act with respect to the disposition of all Notes covered by each Registration Statement during the applicable period in accordance with the intended method or methods of
distribution by the selling Holders thereof; 
  
 (c) in the case
of a Shelf Registration, (i) notify each Holder of Registrable Securities, at least 5 business days prior to filing, that a Shelf Registration Statement with respect to the Registrable Securities is being filed and advising such Holders that the
distribution of Registrable Securities will be made in accordance with the method elected by the Majority Holders; (ii) furnish to each Holder of Registrable Securities included in the Shelf Registration, to counsel for the Initial Purchaser, to
counsel for the Holders, if any, and to each underwriter of an underwritten offering of Registrable Securities, if any, without charge, as many copies of each Prospectus, including each preliminary Prospectus, and any amendment or supplement thereto
and such other documents as such Holder, counsel or underwriter may reasonably request, including financial statements and schedules and, if such Holder, counsel or underwriter so requests, all exhibits (including those incorporated by reference) in
order to facilitate the public sale or other disposition of the Registrable Securities; and (iii) subject to the penultimate paragraph of this Section 3, the Company hereby consents to the use of the Prospectus, including each preliminary
Prospectus, or any amendment or supplement thereto by each of the Holders of Registrable Securities included in the Shelf Registration and underwriters of Registrable Securities in connection with the offering and sale of the Registrable Securities
covered by any Prospectus or any amendment or supplement thereto; 
  
 (d) use its reasonable best efforts to register or qualify the Registrable Securities under all applicable state securities or “blue sky” laws of such jurisdictions as any selling Holder of Registrable Securities covered by a
Shelf Registration Statement and each underwriter of an underwritten offering of Registrable Securities shall reasonably request, to cooperate with the Holders and the underwriters of any Registrable Securities in connection with any filings
required to be made with the NASD, to keep each such registration or qualification effective during the period such Registration Statement is required to be effective and do any and all other acts and things which may be reasonably necessary or
advisable to enable such Holder to consummate the disposition in each such jurisdiction of such Registrable Securities owned by such Holder; provided, however, that the Company shall not be required to (i) qualify as a foreign corporation or as a
dealer in securities in any jurisdiction where it would not otherwise be required to qualify but for this Section 3(d) or (ii) take any action which would subject it to general service of process or taxation in any such jurisdiction if it is not
then so subject; 
  

 14 

 (e) in the case of a Shelf Registration, notify each Holder of Registrable Securities included in the
Shelf Registration and counsel for such Holders promptly and, if requested by such Holder or counsel, confirm such advice in writing promptly (i) when a Registration Statement has become effective and when any post-effective amendments and
supplements thereto become effective, (ii) of any request by the SEC or any state securities authority for post-effective amendments or supplements to a Registration Statement or Prospectus or for additional information after a Registration
Statement has become effective, (iii) of the issuance by the SEC or any state securities authority of any stop order suspending the effectiveness of a Registration Statement or the initiation of any proceedings for that purpose, (iv) if between the
effective date of a Registration Statement and the closing of any sale of Registrable Securities covered thereby the representations and warranties of the Company contained in any underwriting agreement, securities sales agreement or other similar
agreement, if any, relating to such offering cease to be true and correct, (v) of the receipt by the Company of any notification with respect to the suspension of the qualification of the Registrable Securities for sale in any jurisdiction or the
initiation or threatening of any proceeding for such purpose, (vi) of the suspension of use of the Prospectus as a result of the happening of any event or the discovery of any facts or the taking of any action during the period a Shelf Registration
Statement is effective which is contemplated in Section 2(d)(i)(A) or 2(d)(i)(B) or which makes any statement made in such Shelf Registration Statement or the related Prospectus untrue in any material respect or which constitutes an omission to
state a material fact in such Shelf Registration Statement or Prospectus and (vii) of any determination by the Company that a post-effective amendment to a Registration Statement would be appropriate. Without limitation to any other provisions of
this Agreement, the Company agrees that this Section 3(e) shall also be applicable, mutatis mutandis, with respect to the Exchange Offer Registration Statement and the Prospectus included therein to the extent that such Prospectus is being used by
Participating Broker-Dealers as contemplated by Section 3(f); 
  
 (f) (A) in the case of an Exchange Offer, (i) include in the Exchange Offer Registration Statement (x) a “Plan of Distribution” section substantially in the form set forth in Annex A hereto or other such form as is reasonably
acceptable to the Initial Purchaser covering the use of the Prospectus included in the Exchange Offer Registration Statement by broker-dealers who have exchanged their Registrable Securities for Exchange Securities for the resale of such Exchange
Securities and (y) a statement to the effect that any such broker-dealers who wish to use the related Prospectus in connection with the resale of Exchange Securities acquired as a result of market-making or other trading activities will be required
to notify the Company to that effect, together with instructions for giving such notice (which instructions shall include a provision for giving such notice by checking a box or making another appropriate notation on the related letter of
transmittal) (each such broker-dealer who gives notice to the Company as aforesaid being hereinafter called a “Notifying Broker-Dealer”), (ii) furnish to each Notifying Broker-Dealer who desires to participate in the Exchange Offer,
without charge, as many copies of each Prospectus included in the Exchange Offer Registration Statement, including any preliminary prospectus, and any amendment or supplement thereto, as such broker-dealer may reasonably request, (iii) include in
the Exchange Offer Registration Statement a statement that any broker-dealer who holds Registrable Securities acquired for its own account as a result of market-making activities or other trading activities (a “Participating
Broker-Dealer”), and who receives Exchange Securities for Registrable Securities pursuant to the Exchange Offer, may be a statutory underwriter and must deliver a prospectus meeting the requirements of the 1933 Act in 
  

 15 

 connection with any resale of such Exchange Securities, (iv) subject to the penultimate paragraph of this Section 3, the
Company hereby consents to the use of the Prospectus forming part of the Exchange Offer Registration Statement or any amendment or supplement thereto by any Notifying Broker-Dealer in connection with the sale or transfer of Exchange Securities, and
(v) include in the transmittal letter or similar documentation to be executed by an exchange offeree in order to participate in the Exchange Offer the following provision: 
  
 “If the undersigned is not a broker-dealer, the undersigned represents that it is not engaged in, and does not intend
to engage in, a distribution of Exchange Securities. If the undersigned is a broker-dealer that will receive Exchange Securities for its own account in exchange for Registrable Securities, it represents that the Registrable Securities to be
exchanged for Exchange Securities were acquired by it as a result of market-making activities or other trading activities and acknowledges that it will deliver a prospectus meeting the requirements of the 1933 Act in connection with any resale of
such Exchange Securities pursuant to the Exchange Offer; however, by so acknowledging and by delivering a prospectus, the undersigned will not be deemed to admit that it is an “underwriter” within the meaning of the 1933 Act”;

  
 (B) to the extent any Notifying Broker-Dealer participates in
the Exchange Offer, (i) the Company shall use its reasonable best efforts to maintain the effectiveness of the Exchange Offer Registration Statement for a period of time necessary to permit the Prospectus included therein to be lawfully delivered by
all persons subject to the prospectus delivery requirements of the Securities Act for such period of time as such persons must comply with such requirements under the Securities Act and applicable rules and regulations in order to resell the
Exchange Securities; provided, however, that such period shall not be required to exceed 90 days (or such longer period if extended pursuant to the last paragraph of this Section 3) (the “Applicable Period”) following the last date on
which exchanges are accepted pursuant to the Exchange Offer, and (ii) the Company will comply, insofar as relates to the Exchange Offer Registration Statement, the Prospectus included therein and the offering and sale of Exchange Securities pursuant
thereto, with its obligations under Section 2(b)(D), the last paragraph of Section 2(b), Section 3(c), 3(d), 3(e), 3(i), 3(j), 3(k), 3(o) and 3(p), and the last two paragraphs of this Section 3 as if all references therein to a Shelf Registration
Statement, the Prospectus included therein and the Holders of Registrable Securities referred, mutatis mutandis, to the Exchange Offer Registration Statement, the Prospectus included therein and the applicable Notifying Broker-Dealers and,
for purposes of this Section 3(f), all references in any such paragraphs or sections to the “Majority Holders” shall be deemed to mean, solely insofar as relates to this Section 3(f), the Notifying Broker-Dealers who are the Holders of the
majority in aggregate principal amount of the Exchange Securities which are Registrable Securities; 
  
 (C) the Company shall not be required to amend or supplement the Prospectus contained in the Exchange Offer Registration Statement as would otherwise be
contemplated by Section 3(b) or 3(k) hereof, or take any other action as a result of this Section 3(f), at any time after the expiration of the Applicable Period (subject to extension pursuant to the last paragraph of this Section 3) after the last
date on which exchanges are accepted pursuant to the Exchange Offer, and neither Notifying Broker-Dealers nor any other Person shall be authorized by the Company to, and shall not, deliver such Prospectus after such period in connection with resales
contemplated by this Section 3; and 
  

 16 

 (D) In the case of any Exchange Offer Registration Statement, the Company agrees to deliver to the
Initial Purchaser on behalf of the Participating Broker-Dealer upon the effectiveness of the Exchange Offer Registration Statement, if requested (i) an opinion of counsel or opinions of counsel reasonably satisfactory to the Initial Purchaser, (ii)
officers’ certificates substantially in the form customarily delivered in a public offering of debt securities and (iii) a comfort letter or comfort letters in customary form to the extent permitted by Statement on Auditing Standards No. 72 of
the American Institute of Certified Public Accountants (or if such a comfort letter is not permitted, an agreed upon procedures letter in customary form) from the Company’s independent certified public accountants (and, if necessary, any other
independent certified public accountants of any subsidiary of the Company or of any business acquired by the Company for which financial statements are, or are required to be, included in the Registration Statement) at least as broad in scope and
coverage as the comfort letter or comfort letters delivered to the Initial Purchaser in connection with the initial sale of the Notes to the Initial Purchaser; 
  

(g) (i) in the case of an Exchange Offer, furnish counsel for the Initial Purchaser and (ii) in the case of a Shelf Registration, furnish counsel for
the Holders of Registrable Securities and counsel for any underwriters of Registrable Securities copies of any request by the SEC or any state securities authority for amendments or supplements to a Registration Statement or Prospectus or for
additional information; 
  
 (h) use its reasonable best effort to
obtain the withdrawal of any order suspending the effectiveness of a Registration Statement as soon as practicable and provide immediate notice to each Holder of the withdrawal of any such order; 
  
 (i) in the case of a Shelf Registration, furnish to each Holder of
Registrable Securities included in the Shelf Registration, without charge, at least one conformed copy of each Registration Statement and any post-effective amendments thereto (without documents incorporated or deemed to be incorporated therein by
reference or exhibits thereto, unless requested), if such documents are not available via the SEC EDGAR database; 
  
 (j) in the case of a Shelf Registration, cooperate with the selling Holders of Registrable Securities to facilitate the timely preparation and delivery of
certificates representing Registrable Securities to be sold and not bearing any restrictive legends other than requiring transfers in multiples of $1,000; and cause such Registrable Securities to be in such denominations (consistent with the
provisions of the Indenture) and in a form eligible for deposit with the Depositary and registered in such names as the selling Holders or the underwriters, if any, may reasonably request in writing at least two business days prior to the closing of
any sale of Registrable Securities pursuant to such Shelf Registration; 
  
 (k) in the case of a Shelf Registration, upon the occurrence of any event or the discovery of any facts as contemplated by Section 3(e)(vi) hereof, use its reasonable best efforts to prepare a supplement or post-effective amendment to a
Registration Statement or the related Prospectus or any document incorporated or deemed to be incorporated therein by reference or file any other required document so that, as thereafter delivered to the purchasers of the Registrable Securities,
such Prospectus will not contain at the time of such delivery any untrue statement of a material fact or omit to state a material fact necessary in order to make the 
  

 17 

 statements therein, in light of the circumstances under which they were made, not misleading. The Company agrees to
notify each Holder to suspend use of the Prospectus as promptly as practicable after the occurrence of such an event, and each Holder hereby agrees to suspend use of the Prospectus until the Company has amended or supplemented the Prospectus to
correct such misstatement or omission or, alternatively, to notify the Holders that no such amendment or supplement is necessary. At such time as such public disclosure is otherwise made or the Company determines that such disclosure is not
necessary, in each case to correct any misstatement of a material fact or to include any omitted material fact, the Company agrees promptly to notify each Holder of such determination and to furnish each Holder such number of copies of the
Prospectus, as amended or supplemented, as such Holder may reasonably request; 
  
 (l) obtain CUSIP numbers for all Exchange Securities or Registrable Securities, as the case may be, not later than the effective date of a Registration Statement, and provide the Trustee with printed or word-processed
certificates for the Exchange Securities or Registrable Securities, as the case may be, in a form eligible for deposit with the Depositary; 
  
 (m) (i) cause the Indenture to be qualified under the TIA in connection with the registration of the Exchange Securities or Registrable Securities, as the
case may be, (ii) cooperate with the Trustee and the Holders to effect such changes, if any, to the Indenture as may be required for the Indenture to be so qualified in accordance with the terms of the TIA and (iii) execute, and use its best efforts
to cause the Trustee to execute, all documents as may be required to effect such changes, if any, and all other forms and documents required to be filed with the SEC to enable the Indenture to be so qualified in a timely manner; 
  
 (n) in the case of a Shelf Registration, the Holders of a majority in
principal amount of the Registrable Securities registered pursuant to such Shelf Registration Statement shall have the right to direct the Company to effect not more than one underwritten registration and, in connection with such underwritten
registration, the Company shall enter into agreements (including underwriting agreements or similar agreements) and take all other customary and appropriate actions (including those reasonably requested by the Holders of a majority in principal
amount of the Registrable Securities being sold) in order to expedite or facilitate the disposition of such Registrable Securities; provided, however, the Company will not be required to effect such underwritten registration or enter into any
agreements in connection therewith within 90 days after consummation of any other underwritten public offering of the Company. In connection with the underwritten registration undertaken at the direction of the Holders, the Company shall, in a
manner that is reasonable and customary: 
  
 (i)
make representations and warranties to the Holders of such Registrable Securities and the underwriters in such form, substance and scope as are customarily made by issuers to underwriters in similar underwritten offerings as may be reasonably
requested by such Holders and the managing underwriter(s); 
  
 (ii) obtain opinions of counsel to the Company (which counsel and opinions (in form, scope and substance) shall be reasonably satisfactory to the managing underwriter(s), and the Holders of a majority in principal
amount of the Registrable Securities being sold) addressed to each selling Holder and the 
  

 18 

 underwriters, covering the matters customarily covered in opinions requested in sales of debt securities
or underwritten offerings of debt securities and such other matters as may be reasonably requested by such Holders and the managing underwriter(s); 
  
 (iii) obtain “cold comfort” letters and updates thereof with respect to such Shelf Registration Statement and the Prospectus
included therein, all amendments and supplements thereto and all documents incorporated or deemed to be incorporated by reference therein from the Company’s independent certified public accountants and from the independent certified public
accountants for any other Person or any business or assets whose financial statements are included or incorporated by reference in the Shelf Registration Statement, each addressed to the underwriters, and use reasonable best efforts to have such
letters addressed to the selling Holders of Registrable Securities, such letters to be in customary form and covering matters of the type customarily covered in “cold comfort” letters to underwriters in connection with similar underwritten
offerings and such letters to be delivered at the time of the pricing of such underwritten registration with an update to such letter to be delivered at the time of closing of such underwritten registration; 
  
 (iv) if an underwriting agreement or other similar agreement
is entered into, cause the same to set forth indemnification and contributions provisions and procedures substantially equivalent to the indemnification and contributions provisions and procedures set forth in Section 5 hereof with respect to the
underwriters and all other parties to be indemnified pursuant to Section 5 hereof or such other indemnification and contributions as shall be satisfactory to the Company, the managing underwriter(s) and the Holders of the majority in principal
amount of the Registrable Securities being sold; and 
  
 (v) deliver such other documents and certificates as may be reasonably requested and as are customarily delivered in similar underwritten offerings of debt securities. 
  
 The documents referred to in Sections 3(n)(ii) and 3(n)(v) shall be delivered at the closing under any underwriting or similar agreement as
and to the extent required thereunder. In the case of any such underwritten offering, the Company shall provide written notice to the Holders of all Registrable Securities of such underwritten offering at least 30 days prior to the filing of a
prospectus supplement for such underwritten offering. Such notice shall (x) offer each such Holder the right to participate in such underwritten offering, (y) specify a date, which shall be no earlier than 15 days following the date of such notice,
by which such Holder must inform the Company of its intent to participate in such underwritten offering and (z) include the instructions such Holder must follow in order to participate in such underwritten offering; 
  
 (o) in the case of a Shelf Registration, make available for inspection by
representatives of the Holders of the Registrable Securities and any underwriters participating in any disposition pursuant to a Shelf Registration Statement and any counsel or accountant retained by such Holders or underwriters, all financial
statements and other records, documents 
  

 19 

 and properties of the Company reasonably requested by any such Persons, and cause the respective officers, directors,
employees, and any other agents of the Company to supply all information reasonably requested by any such Persons in connection with a Shelf Registration Statement; 
  
 (p) (i) in the case of an Exchange Offer, a reasonable time prior to the filing of any Exchange Offer Registration
Statement, any Prospectus forming a part thereof, any amendment to an Exchange Offer Registration Statement or amendment or supplement to such Prospectus, provide copies of such documents to the Initial Purchaser, and make such changes in any such
documents prior to the filing thereof as the Initial Purchaser or its counsel may reasonably request; (ii) in the case of a Shelf Registration, a reasonable time prior to filing any Shelf Registration Statement, any Prospectus forming a part
thereof, any amendment to such Shelf Registration Statement or amendment or supplement to such Prospectus, provide copies of such document to the Holders of Registrable Securities, to the Initial Purchaser, to the underwriter or underwriters, of an
underwritten offering of Registrable Securities, and to counsel for any such Holders, Initial Purchaser or underwriters, and make such changes in any such document prior to the filing thereof as the Holders of Registrable Securities, the Initial
Purchaser, any such underwriter or underwriters or any of their respective counsel may reasonably request; and (iii) cause the representatives of the Company to be available for discussion of such documents as shall be reasonably requested by the
Holders of Registrable Securities, the Initial Purchaser on behalf of such Holders or the underwriters, and shall not at any time make any filing of any such document of which such Holders, the Initial Purchaser on behalf of such Holders, its
counsel or any underwriter shall not have previously been advised and furnished a copy or to which such Holders, the Initial Purchaser on behalf of such Holders, its counsel or any underwriter shall reasonably object within a reasonable time period;

  
 (q) in the case of a Shelf Registration, use its reasonable
best efforts to cause the Registrable Securities to be rated with the appropriate rating agencies, if so requested by the Majority Holders or by the underwriters of an underwritten offering, unless the Registrable Securities are already so rated;

  
 (r) otherwise use its reasonable best efforts to comply with
all applicable rules and regulations of the SEC and, with respect to each Registration Statement and each post-effective amendment, if any, thereto and each filing by the Company of an Annual Report on Form 10-K, make available to its security
holders, as soon as reasonably practicable, an earnings statement covering at least twelve months which shall satisfy the provisions of Section 11(a) of the 1933 Act and Rule 158 thereunder; 
  
 (s) cooperate and assist in any filings required to be made with the NASD and
in the performance of any due diligence investigation by any underwriter and its counsel; and 
  
 (t) in the case of a Shelf Registration, a reasonable time prior to the filing of any Registration Statement, any Prospectus, any amendment to a Registration Statement or amendment or supplement to a Prospectus or any
document which is to be incorporated by reference into a Registration Statement or a Prospectus after the initial filing of a Registration Statement, provide copies of such document to the Initial Purchaser on behalf of such Holders; and make
representatives of the Company as shall be reasonably requested by the Holders of Registrable Securities, or the Initial Purchaser on behalf of such Holders, available for discussion of such document. 
  

 20 

 In the case of a Shelf Registration Statement, the Company may (as a condition to such Holder’s
participation in the Shelf Registration) require each Holder of Registrable Securities to furnish to the Company in writing, within 15 days after receipt of a request therefor, such information regarding such Holder and the proposed distribution by
such Holder of such Registrable Securities as the Company may from time to time reasonably request in writing and require such Holder to agree in writing to be bound by all provisions of this Agreement applicable to such Holder. Each Holder as to
which any Shelf Registration is being effected agrees to furnish to the Company all information with respect to such Holder necessary to make the information previously furnished to the Company by such Holder not materially misleading. 

 
 In the case of a Shelf Registration Statement, each Holder agrees and, in
the event that any Participating Broker-Dealer is using the Prospectus included in the Exchange Offer Registration Statement in connection with the sale of Exchange Securities pursuant to Section 3(f), each such Participating Broker-Dealer agrees
that, upon receipt of any notice from the Company of the happening of any event or the discovery of any facts of the kind described in Section 3(e)(ii), 3(e)(iii) or 3(e)(v) through 3(e)(vii) hereof, such Holder or Participating Broker-Dealer, as
the case may be, will forthwith discontinue disposition of Registrable Securities pursuant to a Registration Statement until receipt by such Holder or Participating Broker-Dealer, as the case may be, of (i) the copies of the supplemented or amended
Prospectus contemplated by Section 3(k) hereof or (ii) written notice from the Company that the Shelf Registration Statement or the Exchange Offer Registration Statement, respectively, are once again effective or that no supplement or amendment is
required. If so directed by the Company, such Holder or Participating Broker-Dealer, as the case may be, will deliver to the Company (at the Company’s expense) all copies in its possession, other than permanent file copies then in its
possession, of the Prospectus covering such Registrable Securities current at the time of receipt of such notice. Nothing in this paragraph shall prevent the accrual of Additional Interest on any Notes or Exchange Securities. 
  
 If the Company shall give any such notice to suspend the disposition of
Registrable Securities pursuant to the immediately preceding paragraph, the Company shall use its reasonable best efforts to file and have declared effective (if an amendment) as soon as practicable thereafter an amendment or supplement to the Shelf
Registration Statement or the Exchange Offer Registration Statement or both, as the case may be, or the Prospectus included therein and shall extend the period during which the Shelf Registration Statement or the Exchange Offer Registration
Statement or both, as the case may be, shall be maintained effective pursuant to this Agreement (and, if applicable, the period during which Participating Broker-Dealers may use the Prospectus included in the Exchange Offer Registration Statement
pursuant to Section 3(f) hereof) by the number of days during the period from and including the date of the giving of such notice to and including the earlier of the date when the Holders or Participating Broker-Dealers, respectively, shall have
received copies of the supplemented or amended Prospectus necessary to resume such dispositions and the effective date of written notice from the Company to the Holders or Participating Broker-Dealers, respectively, that the Shelf Registration
Statement or the Exchange Offer Registration Statement, respectively, are once again effective or that no supplement or amendment is required. 
  

 21 

 4. Underwritten Registrations. If any of the Registrable Securities covered by any Shelf Registration are
to be sold in an underwritten offering, the investment banker or investment bankers and manager or managers that will manage the offering will be selected by the Majority Holders of such Registrable Securities included in such offering, subject to
the consent of the Company, which consent shall not be unreasonably withheld. 
  
 No Holder of Registrable Securities may participate in any underwritten registration hereunder unless such Holder (a) agrees to sell such Holder’s Registrable Securities on the basis provided in any underwriting
arrangements approved by the Persons entitled hereunder to approve such arrangements and (b) completes and executes all questionnaires, powers of attorney, indemnities, underwriting agreements and other documents required under the terms of such
underwriting arrangements. 
  
 5. Indemnification and
Contribution. 
  
 (a) The Company agrees to indemnify and hold
harmless the Initial Purchaser, each Holder, each Participating Broker-Dealer, each underwriter who participates in an offering of Registrable Securities (each, an “Underwriter”), and each Person, if any, who controls the Initial Purchaser
or any Holder Participating Broker-Dealer or Underwriter within the meaning of either Section 15 of the 1933 Act or Section 20 of the 1934 Act, as follows: 
  
 (i) against any and all loss, liability, claim, damage and expense whatsoever, as incurred, arising out of any untrue statement or alleged
untrue statement of a material fact contained in any Registration Statement (and any amendment thereto) pursuant to which Exchange Securities or Registrable Securities were registered under the 1933 Act, including all documents incorporated therein
by reference, or any omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements therein not misleading, or arising out of any untrue statement or alleged untrue statement of a material
fact contained in any preliminary prospectus or Prospectus (and any amendment thereto) or any omission or alleged omission therefrom of a material fact necessary in order to make the statements therein, in the light of the circumstances under which
they were made, not misleading; 
  
 (ii) against
any and all loss, liability, claim, damage and expense whatsoever, as incurred, to the extent of the aggregate amount paid in settlement of any litigation, or any investigation or proceeding by any governmental agency or body, commenced or
threatened, or of any claim whatsoever based upon any such untrue statement or omission, or any such alleged untrue statement or omission; provided that any such settlement is effected with the written consent of the Company; and 
  
 (iii) against any and all expense whatsoever, as incurred
(including the fees and disbursements of one counsel chosen by any indemnified party), reasonably incurred in investigating, preparing or defending against any litigation, or any investigation or proceeding by any governmental agency or body,
commenced or threatened, or any claim whatsoever based upon any such untrue statement or omission, or any such alleged untrue statement or omission, to the extent that any such expense is not paid under subparagraph (i) or (ii) above; 
  

 22 

 provided, however, that this indemnity agreement shall not apply to any loss, liability, claim, damage or expense to the
extent arising out of any untrue statement or omission or alleged untrue statement or omission made in reliance upon and in conformity with written information furnished to the Company by the Initial Purchaser or any Holder, Participating
Broker-Dealer or Underwriter with respect to such Initial Purchaser, Holder, Participating Broker-Dealer or Underwriter expressly for use in the Registration Statement (or any amendment thereto) or the Prospectus (or any amendment or supplement
thereto) or made in reliance upon the Statements of Eligibility and Qualification of Trustees (Form T-1) under the 1939 Act filed as exhibits to the Registration Statement; 
  
 further provided, that this indemnity does not apply to any Holder, Participating Broker-Dealer, Underwriter or controlling person, with
respect to any untrue statement or omission or alleged omission in any preliminary Prospectus to the extent that any such loss, liability, claim, damage or expense of any such Holder, Participating Broker-Dealer, Underwriter or controlling person
results from the fact that such Holder, Underwriter or Participating Broker-Dealer sold Registrable Securities to a person to whom there was not sent or given, at or prior to the written confirmation of such sale, a copy of the final Prospectus as
then amended or supplemented if the Company had previously furnished copies thereof to such Holder, Underwriter or Participating Broker-Dealer with sufficient time for such Holder, Underwriter or Participating Broker-Dealer to distribute such final
Prospectus and the loss, liability, claim, damage or expense of such Holder, Underwriter, Participating Broker-Dealer, or controlling person results from an untrue statement or omission of a material fact contained in the preliminary Prospectus
which was corrected in the final Prospectus. Any amounts advanced by the Company to an indemnified party pursuant to this Section 5 as a result of such losses shall be returned to the Company if it shall be finally determined by such a court in a
judgment not subject to appeal or final review that such indemnified party was not entitled to indemnification by the Company. 
  
 (b) The Initial Purchaser, each Holder, each Participating Broker-Dealer and each Underwriter severally but not jointly, agrees to indemnify and hold
harmless the Company, each director and officer of the Company, each other Initial Purchaser, selling Holder, Participating Broker-Dealer and Underwriter, and each Person, if any, who controls the Company or any Initial Purchaser, other selling
Holder, Participating Broker-Dealer or Underwriter within the meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act against any and all loss, liability, claim, damage and expense described in the indemnity contained in Section 5(a)
hereof, as incurred, with respect to untrue statements or omissions, or alleged untrue statements or omissions, made in any Registration Statement pursuant to which Exchange Securities or Registrable Securities were registered under the 1933 Act (or
any amendment thereto) or any Prospectus included therein (or any amendment or supplement thereto) in reliance upon and in conformity with written information with respect to such Initial Purchaser, Holder, Participating Broker-Dealer or Underwriter
furnished to the Company by such Initial Purchaser, Holder, Participating Broker-Dealer, or Underwriter, respectively, expressly for use in the Shelf Registration Statement (or any amendment thereto) or such Prospectus (or any amendment or
supplement thereto); provided, however, that no such Initial Purchaser, Holder, Participating Broker-Dealer or Underwriter shall be liable for any claims 
  

 23 

 hereunder in excess of the amount of net proceeds received by such Initial Purchaser, Holder, Participating Broker-Dealer
or Underwriter from the sale of Registrable Securities pursuant to such Shelf Registration Statement. 
  
 (c) Each indemnified party shall give notice as promptly as reasonably practicable to each indemnifying party of any action commenced against it in
respect of which indemnity may be sought hereunder, but failure so to notify an indemnifying party shall not relieve such indemnifying party from any liability which it may have otherwise than on account of this indemnity agreement. An indemnifying
party may participate at its own expense in the defense of such action; provided, however, that counsel to the indemnifying party shall not (except with the consent of the indemnified party) also be counsel to the indemnified party. In no event
shall the indemnifying parties be liable for the fees and expenses of more than one counsel (in addition to any local counsel) separate from their own counsel for all indemnified parties in connection with any one action or separate but similar or
related actions in the same jurisdiction arising out of the same general allegations or circumstances. No indemnifying party shall, without the prior written consent of the indemnified parties, settle or compromise or consent to the entry of any
judgment with respect to any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or any claim whatsoever in respect of which indemnification or contribution could be sought under this Section 5
(whether or not the indemnified parties are actual or potential parties thereto), unless such settlement, compromise or consent (i) includes an unconditional release of each indemnified party from all liability arising out of such litigation,
investigation, proceeding or claim and (ii) does not include a statement as to or an admission of fault, culpability or a failure to act by or on behalf of any indemnified party. 
  
 (d) In order to provide for just and equitable contribution in circumstances in which the indemnity agreement provided for
in this Section 5 is for any reason unavailable to or insufficient to hold harmless an indemnified party in respect of any losses, liabilities, claims, damages or expenses referred to therein, then each indemnifying party shall contribute to the
aggregate amount of such losses, liabilities, claims, damages and expenses incurred by such indemnified party, as incurred, in such proportion as is appropriate to reflect the relative fault of the indemnifying party or parties on the one hand and
of the indemnified party or parties on the other hand in connection with the statements or omissions that resulted in such losses, liabilities, claims, damages or expenses, as well as any other relevant equitable considerations. The relative fault
of such indemnifying party or parties on the one hand and the indemnified party or parties on the other hand shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or omission or
alleged omission to state a material fact relates to information supplied by such indemnifying party or parties or such indemnified party or parties, and the parties’ relative intent, knowledge, access to information and opportunity to correct
or prevent such statement or omission. 
  
 (e) The Company, the
Initial Purchaser, the Holders, the Participating Broker-Dealers and the Underwriters agree that it would not be just or equitable if contribution pursuant to this Section 5 were determined by pro rata allocation or by any other method of allocation
that does not take account of the equitable considerations referred to in paragraph (d) above. The aggregate amount of losses, liabilities, claims, damages and expenses incurred by an indemnified party and referred to above in this Section 5 shall
be deemed to include any legal or other 
  

 24 

 expenses reasonably incurred by such indemnified party in investigating, preparing or defending against any litigation,
or any investigation or proceeding by any governmental agency or body, commenced or threatened, or any claim whatsoever based upon any such untrue or alleged untrue statement or omission or alleged omission. Notwithstanding the provisions of this
Section 5, neither the Initial Purchaser nor any Holder, Participating Broker-Dealer or Underwriter shall be required to contribute any amount in excess of the amount by which the total price at which Registrable Securities sold by it were offered
exceeds the amount of any damages that such Initial Purchaser, Holder, Participating Broker-Dealer or Underwriter has otherwise been required to pay by reason of any such untrue or alleged untrue statement or omission or alleged omission.

  
 No Person guilty of fraudulent misrepresentation (within the
meaning of Section 11(f) of the 1933 Act) shall be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation. 
  
 For purposes of this Section 5, each Person, if any, who controls the Initial Purchaser or any Holder, Participating Broker-Dealer or Underwriter within
the meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act shall have the same rights to contribution as the Initial Purchaser or such Holder, Participating Broker-Dealer or Underwriter, as the case may be, and each director and officer
of the Company who signed the Registration Statement and each Person, if any, who controls the Company within the meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act shall have the same rights to contribution as the Company. The
respective obligations of the Initial Purchaser, Holders, Participating Broker-Dealers and Underwriters to contribute pursuant to this Section 5 are several in proportion to the principal amount of Notes purchased by them and not joint. 

 
 The indemnity and contribution provisions contained in this Section 5
shall remain operative and in full force and effect regardless of (i) any termination of this Agreement, (ii) any investigation made by or on behalf of the Initial Purchaser or any Holder, Participating Broker-Dealer, Underwriter, or any Person
controlling the Initial Purchaser or any Holder, Participating Broker-Dealer or Underwriter, or by or on behalf of the Company, its officers or directors or any Person controlling the Company, (iii) acceptance of any of the Exchange Securities and
(iv) any sale of Registrable Securities or Exchange Securities pursuant to a Shelf Registration Statement. 
  
 6. Miscellaneous. 
  
 (a) Rule 144 and Rule 144A. For so long as the Company is subject to the reporting requirements of Section 13 or 15 of the 1934 Act, the Company covenants
that it will file all reports required to be filed by it under Section 13(a) or 15(d) of the 1934 Act and the rules and regulations adopted by the SEC thereunder, that if it ceases to be so required to file such reports, it will upon the request of
any Holder or beneficial owner of Registrable Securities (i) make publicly available such information (including, without limitation, the information specified in Rule 144(c)(2) under the 1933 Act) as is necessary to permit sales pursuant to Rule
144 under the 1933 Act, (ii) deliver or cause to be delivered, promptly following a request by any Holder or beneficial owner of Registrable Securities or any prospective purchaser or transferee designated by such Holder or beneficial owner, such
information (including, without 
  

 25 

 limitation, the information specified in Rule 144A(d)(4) under the 1933 Act) as is necessary to permit sales pursuant to
Rule 144A under the 1933 Act, and (iii) take such further action that is reasonable in the circumstances, in each case to the extent required from time to time to enable such Holder to sell its Registrable Securities without registration under the
1933 Act within the limitation of the exemptions provided by (x) Rule 144 under the 1933 Act, as such Rule may be amended from time to time, (y) Rule 144A under the 1933 Act, as such Rule may be amended from time to time, or (z) any similar rules or
regulations hereafter adopted by the SEC. Upon the request of any Holder or beneficial owner of Registrable Securities, the Company will deliver to such Holder or beneficial owner a written statement as to whether it has complied with such
requirements. 
  
 (b) No Inconsistent Agreements. The Company has
not entered into nor will the Company on or after the date of this Agreement enter into any agreement which is inconsistent with the rights granted to the Holders of Registrable Securities in this Agreement or otherwise conflicts with the provisions
hereof, without the written consent of the Holders of at least a majority in aggregate principal amount of the outstanding Registrable Securities. 
  
 (c) Amendments and Waivers. The provisions of this Agreement, including the provisions of this sentence, may not be amended, modified or supplemented, and
waivers or consents to departures from the provisions hereof may not be given, unless the Company has obtained the written consent of Holders of at least a majority in aggregate principal amount of the outstanding Registrable Securities affected by
such amendment, modification, supplement, waiver or departure. 
  
 Notwithstanding the foregoing sentence, (i) this Agreement may be amended, without the consent of any Holder of Registrable Securities, by written agreement signed by the Company and the Initial Purchaser, to cure any ambiguity, correct or
supplement any provision of this Agreement that may be inconsistent with any other provision of this Agreement or to make any other provision with respect to matters or questions arising under this Agreement which shall not be inconsistent with
other provisions of this Agreement, (ii) this Agreement may be amended, modified or supplemented, and waivers and consents to departures from the provisions hereof may be given, by written agreement signed by the Company and the Initial Purchaser to
the extent that any such amendment, modification, supplement, waiver or consent is, in the reasonable judgment of both the Company and the Initial Purchaser, necessary or appropriate to comply with applicable law (including any interpretation of the
Staff of the SEC) or any change therein and (iii) to the extent any provision of this Agreement relates to the Initial Purchaser, such provision may be amended, modified or supplemented, and waivers or consents to departures from such provisions may
be give, by written agreement signed by the Initial Purchaser and the Company. Each Holder of Registrable Securities shall be bound by any amendment or waiver effected pursuant to this Section 6(c), whether or not any notice, writing or marking
indicating such amendment or waiver appears on such security or is delivered to such Holder. 
  
 (d) Notices. All notices and other communications provided for or permitted hereunder shall be made in writing by hand-delivery, registered first-class mail, telecopier, or any courier guaranteeing overnight delivery
(i) if to a Holder or Participating Broker-Dealer (other than the Initial Purchaser), at the most current address set forth on the records of the 
  

 26 

 registrar under the Indenture, (ii) if to the Initial Purchaser, at the most current address given by the Initial
Purchaser to the Company by means of a notice given in accordance with the provisions of this Section 6(d), which address initially is the address set forth in the Purchase Agreement; and (iii) if to the Company, initially at the address set forth
in the Purchase Agreement and thereafter at such other address, notice of which is given in accordance with the provisions of this Section 6(d). 
  
 All such notices and communications shall be deemed to have been duly given: at the time delivered by hand, if personally delivered; five business days
after being deposited in the mail, first class, postage prepaid, if mailed; when receipt is acknowledged, if telecopied; and on the next business day if timely delivered to a courier guaranteeing overnight delivery. 
  
 Copies of all such notices, demands or other communications shall be
concurrently delivered by the Person giving the same to the Trustee, at the address specified in the Indenture. 
  
 (e) Successors and Assigns. This Agreement shall inure to the benefit of and be binding upon the successors, assigns and transferees of each of the
parties, including, without limitation and without the need for an express assignment, subsequent Holders; provided that nothing herein shall be deemed to permit any assignment, transfer or other disposition of Registrable Securities in violation of
the terms hereof or of the Purchase Agreement or the Indenture. If any transferee of any Holder shall acquire Registrable Securities, in any manner, whether by operation of law or otherwise, such Registrable Securities shall be held subject to all
of the terms of this Agreement, and by taking and holding such Registrable Securities, such Person shall be conclusively deemed to have agreed to be bound by and to perform all of the terms and provisions of this Agreement, including the
restrictions on resale set forth in this Agreement and, if applicable, the Purchase Agreement, and such Person shall be entitled to receive the benefits hereof. 
  

(f) Third Party Beneficiary. Each Holder, Participating Broker-Dealer and Underwriter shall be a third party beneficiary of the agreements made
hereunder between the Company, on the one hand, and the Initial Purchaser, on the other hand, and shall have the right to enforce such agreements directly to the extent it deems such enforcement necessary or advisable to protect its rights or the
rights of other Holders hereunder. Each Holder, by its acquisition of Notes, shall be deemed to have agreed to the provisions of Section 5(b) hereof. 
  
 (g) Counterparts. This Agreement may be executed in any number of counterparts and by the parties hereto in separate counterparts, each of which when so
executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. 
  
 (h) Headings. The headings in this Agreement are for convenience of reference only and shall not limit or otherwise affect the meaning hereof. 

 
 (i) Restriction on Resales. If (i) the Company or any of its subsidiaries
or affiliates (as defined in Rule 144 under the 1933 Act) shall redeem, purchase or otherwise acquire any Registrable Security or any Exchange Security which is a “restricted security” within 
  

 27 

 the meaning of Rule 144 under the 1933 Act, the Company will deliver or cause to be delivered such Registrable Security
or Exchange Security, as the case may be, to the Trustee for cancellation and neither the Company nor any of its subsidiaries or affiliates will hold or resell such Registrable Security or Exchange Security or issue any new Security or Exchange
Security to replace the same. 
  
 (j) GOVERNING LAW. THIS
AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK. 
  
 (k) Severability. In the event that any one or more of the provisions contained herein, or the application thereof in any circumstance, is held invalid,
illegal or unenforceable, the validity, legality and enforceability of any such provision in every other respect and of the remaining provisions contained herein shall not be affected or impaired thereby. 
  
 [SIGNATURE PAGE FOLLOWS] 
  

 28 

 IN WITNESS WHEREOF, the parties hereto have executed this Registration Rights Agreement as of the date
first written above. 
  

			
	GREATER BAY BANCORP
		
	By:	 	 /s/ James S. Westfall

	Name:	 	James S. Westfall
	Title:	 	 Executive Vice President and
 Chief Financial
Officer

  

 29 

 This Registration Rights Agreement is confirmed and accepted as of the date first above written by the undersigned.

  

			
	KEEFE, BRUYETTE & WOODS, INC.
		
	By:	 	 /s/ Maurice Beshlian

	Name:	 	Maurice Beshlian
	Title:	 	Managing Director

  

 30 

 ANNEX A 
  
 PLAN OF DISTRIBUTION 
  
 Each broker-dealer that receives new notes for its own account under the exchange offer must acknowledge that it will deliver a prospectus in connection
with any resale of those notes. This prospectus, as it may be amended or supplemented from time to time, may be used by a broker-dealer for resales of new notes received in exchange for original notes that had been acquired as a result of
market-making or other trading activities. We have agreed that, for a period of 90 days after the expiration date of the exchange offer, we will make this prospectus, as it may be amended or supplemented, available to any broker-dealer for use in
connection with any such resale. Any broker-dealers required to use this prospectus and any amendments or supplements to this prospectus for resales of the new notes must notify us of this fact by checking the box on the letter of transmittal
requesting additional copies of these documents. 
  
 Notwithstanding the foregoing, we are entitled under the registration rights agreement to suspend the use of this prospectus by broker-dealers under specified circumstances. For example, we may suspend the use of this prospectus if:

  

	•	 	the SEC or any state securities authority requests an amendment or supplement to this prospectus or the related registration statement or additional information;

  

	•	 	the SEC or any state securities authority issues any stop order suspending the effectiveness of the registration statement or initiates proceedings for that purpose;

  

	•	 	we receive notification of the suspension of the qualification of the new notes for sale in any jurisdiction or the initiation or threatening of any proceeding for that purpose;

  

	•	 	the suspension is required by law; or 

  

	•	 	an event occurs which makes any statement in this prospectus untrue in any material respect or which constitutes an omission to state a material fact in this prospectus.

  
 If we suspend the use of this prospectus, the
90-day period referred to above will be extended by a number of days equal to the period of the suspension. 
  
 We will not receive any proceeds from any sale of new notes by broker-dealers. New notes received by broker-dealers for their own account under the
exchange offer may be sold from time to time in one or more transactions in the over-the-counter market, in negotiated transactions, through the writing of options on those notes or a combination of those methods, at market prices prevailing at the
time of resale, at prices related to prevailing market prices or at negotiated prices. Any resales may be made directly to purchasers or to or through brokers or dealers who may receive compensation in the form of commissions or concessions from the
selling broker-dealer or the purchasers of the new notes. Any broker-dealer that resells new notes 
  

 A-1 

 received by it for its own account under the exchange offer and any broker or dealer that participates in a distribution
of the new notes may be deemed to be an “underwriter” within the meaning of the Securities Act and any profit on any resale of new notes and any commissions or concessions received by these persons may be deemed to be underwriting
compensation under the Securities Act. The letter of transmittal states that, by acknowledging that it will deliver and by delivering a prospectus, a broker-dealer will not be deemed to admit that it is an “underwriter” within the meaning
of the Securities Act. 
  
 We have agreed to pay all expenses
incidental to the exchange offer other than commissions and concessions of any broker or dealer and will indemnify holders of the notes, including any broker-dealers, against certain liabilities, including liabilities under the Securities Act.

  

 A-2License and Supply Agreement

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS DOCUMENT. PORTIONS FOR WHICH CONFIDENTIAL TREATMENT IS
REQUESTED ARE DENOTED BY “[*]”. CONFIDENTIAL INFORMATION OMITTED HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 EXHIBIT 10.1 
  
 LICENSE AND SUPPLY AGREEMENT 
  
 THIS LICENSE AND SUPPLY AGREEMENT is entered into as of the Effective Date (as that term is defined in Section 1.23) by and between BASF Aktiengesellschaft, a corporation organized under the laws of Germany and having
its principal offices at 67056 Ludwigshafen, Germany (“BASF”) and AMVAC Chemical Corporation, a corporation organized under the laws of California, United States of America and having its principal offices at 4695 MacArthur Court,
Suite 1250, Newport Beach, CA 92660 United States of America (“AMVAC”). Each of BASF and AMVAC shall be referred to individually as a “Party” and collectively as the “Parties.” 
  
 W I T N E S S E T H 
  
 WHEREAS, BASF discovered the Compound (as that term is defined in
Section 1.16) as well as certain proprietary and confidential know-how relating thereto, and is in the late stages of developing the Compound as a post-emergent grass and broadleaf herbicide; 
  
 WHEREAS, during [*], BASF permitted AMVAC and others to evaluate
potential commercialization opportunities with respect to use of the Compound in corn in the United States of America, its territories and possessions (the “US”) and Canada; 
  
 WHEREAS, AMVAC desires to expand its corn herbicide portfolio and to
develop further and obtain registrations for the Compound for use in corn in the US and Canada (together with the US, the “Territory”) in return for certain exclusive and nonexclusive commercialization rights and BASF is willing to
grant AMVAC such rights; 
  
 WHEREAS, the Parties entered
into a Letter of Intent dated [*], as amended (the “LOI”), pursuant to which BASF granted AMVAC a [*] patent and know-how license in order to enable AMVAC to undertake development activities with respect to the Compound in the
Territory and, subject to certain provisos, AMVAC agreed to pay the so-called “fee for service” fees to the US’s Environmental Protection Agency (the “EPA”) in order to avoid potentially adverse developments in the
registration process for the Compound in the US; 
  
 WHEREAS, the Parties agreed in Section 1 of the LOI to negotiate exclusively with one another in good faith during the Interim Term (as that term is defined in the LOI) with respect to the terms and conditions of a license and supply
agreement under which BASF would, among other things, grant to AMVAC certain rights in the Territory with respect to the [*] Patent (as that term is defined in Section 1.22) and BASF proprietary intellectual property related to the Compound and
AMVAC would, among other things, obtain registrations in the Territory for the Compound TGAI (as that term is defined in Section 1.18) and end-use products containing such Compound TGAI as an herbicidal active ingredient for use in corn in the
Territory; and 
  
 WHEREAS, the Parties desire to set forth
in this instrument the terms and conditions of said license and supply agreement. 
  
 NOW, THEREFORE, in consideration of the premises as well as the representations, warranties, covenants and agreements hereinafter set forth and intending to be legally bound, the Parties agree as
follows: 
  

 Page 1 of 30 

 ARTICLE I 
 DEFINITIONS 
  
 Unless the
context otherwise requires, the capitalized terms defined below shall have the meanings specified and any term referred to in the singular shall be deemed to include the plural and vice versa as the context requires: 
  
 1.1 “Access Fee” refers to those fees calculated in
accordance with (i) the Additional Data, Additional Initial Registration Work Data, and New Study Data compensation formula set forth in Schedule 1.1 (the “Data Depreciation Formula”) and (ii) the New Study Data compensation
formula set forth in Schedule 1.1 (the “Data Compensation Formula”). 
  
 1.2 “Additional Development Work” means (i) any Interim Term Development Work (as that term is defined in the LOI) completed prior to the Effective Date and (ii) any study or other development
work (a) conducted by or on behalf of AMVAC with respect to the Compound TGAI or the Solo Product on or after the Effective Date including, without limitation, Interim Term Development Work which continues during the Term, (b) required by the EPA or
PMRA in order to file for and obtain the Initial Registrations including, without limitation, those biology studies, accumulation studies, and Product formulation development work to which Schedule 1.2 refers, and (c) the aggregate costs for
which do not exceed [*]. 
  
 1.3 “Additional
Data” means any data resulting from Additional Development Work. For the avoidance of doubt, Interim Term Data (as that term is defined in the LOI) existing as of the Effective Date shall be deemed Additional Data for purposes of this
Agreement. 
  
 1.4 “Affiliate” means any
Person which controls (as hereinafter defined), is controlled by or is under common control with a Party, by way of direct or indirect ownership of more than fifty percent (>50%) of the voting stock or the equity thereof, as the case may be. For
purposes of this Section 1.4, “controlling,” “controlled” and “control” mean the power to direct or influence the management and policies of the Party in question, whether through the ownership of voting securities, by
contract or otherwise. 
  
 1.5 “Agreement”
means this instrument. 
  
 1.6 “AMVAC Confidential
Information” means (i) AMVAC Development Work (as that term is defined in Section 2.1(A)) and (ii) AMVAC Data (as that term is defined in Section 2.4(A)(iii)(c)). 
  
 1.7 “Applicable Law” means any law, statute, regulation and ordinance of any Governmental Authority
having jurisdiction over or related to any Registration, the Compound TGAI, any Product, or BASF Know-How, Information and Data in the Territory. 
  
 1.8 “Applicable Permit” means any waiver, exemption, variance, permit, authorization, license or similar approval required to be
obtained or maintained under any Applicable Law. 
  
 1.9
“BASF Confidential Information” means (i) BASF Know, How, Information and Data, (ii) Joint Additional Initial Registration Work and Joint Additional Initial Registration Work Data (as those terms are defined in Section
2.4(A)(i)), and (iii) Joint New Studies, Joint New Study Data, BASF New Studies, and BASF New Study Data (as those terms are defined in Section 2.4(A)(ii)). 
  
 1.10 “BASF Know-How, Information and Data” means that certain BASF formulation know-how and information with respect to each of
the Compound TGAI, BASF Products, and the Solo Product to which Schedule 1.10 refers, as well as the BASF Study Data, in existence as of the Effective Date, the 
  

 Page 2 of 30 

 1.11 “BASF Patents” means those BASF patents and patent applications listed in
Schedule 1.11 and all divisionals, reissues, reexaminations, term extensions, continuations and continuations-in-part thereof. 
  
 1.12 “BASF Products” means each [*] (i) which contains as its only active ingredients Compound TGAI and that compound commonly
referred to as [*] and (a) for the US, has [*] use rate or such lower use rate to which BASF consents in writing or (b) for Canada, has [*] or such lower use rate to which BASF consents in writing or (ii) which contains as its active ingredients
Compound TGAI and [*], at least one of which is proprietary to BASF and (y) for the US, has [*] or such lower use rate to which BASF consents in writing or (z) for Canada, has [*] or such lower use rate to which BASF consents in writing. 

 
 1.13 “BASF Study Data” means only those data which
results from studies that (i) were initiated by or on behalf of BASF with respect to the Compound TGAI and/or any Product prior to commencement of the Interim Term and (ii) are required by the EPA or PMRA in order to file for and obtain a
Registration(s) for the Compound TGAI. For the avoidance of doubt, all BASF Study Data is identified in Schedule 1.13. 
  
 1.14 “Cite” means (i) with respect to AMVAC, it shall be granted a letter of access, letter of authorization or other similar
right in order to enable it to reference or cite to the BASF Information, Know-How and Data or, if directly referencing or citing to the BASF Know-How, Information and Data is not possible for either regulatory or legal reasons, BASF shall enter
into any and all documents necessary to put AMVAC in the position as if such direct referencing or citation were possible and (ii) with respect to BASF, it shall be granted a letter of access, letter of authorization or other similar right in order
to enable it to reference or cite to the Additional Data, Additional Initial Registration Work Data (as that term is defined in Section 2.4(A)(i)), and New Study Data (as that term is defined in Section 2.4(A)(ii)) or, if directly referencing or
citing to the Additional Data, Additional Initial Registration Work Data, and/or New Study Data is not possible for either regulatory or legal reasons, AMVAC shall enter into any and all documents necessary to put BASF in the position as if such
direct referencing or citation were possible. 
  
 1.15
“Commercialization” means the date on which AMVAC, either directly or through any third party, commences its first sales of any Product in the Territory pursuant to a Registration or [*], whichever occurs first. 
  
 1.16 “Compound” means BASF’s proprietary 670H
compound (including any optical isomer thereof) which exhibits [*] activity, the chemical name and structural formula for which are set forth in Schedule 1.16. 
  
 1.17 “Compound Price” means those prices for Compound TGAI to which Section 5.5 refers. 

 
 1.18 “Compound TGAI” means that form of Compound
technical grade of active ingredient which meets the Specifications. 
  
 1.19 “Confidentiality Agreement” means that confidentiality agreement, effective January 7, 2004, by and between the Parties. 
  

1.20 “Contract Year” means, for the first contract year, the period commencing on the Effective Date and expiring [*] and, for
the second and subsequent contract years during the Term, the twelve (12) month period commencing on [*] and each anniversary thereof, respectively. 
  
 1.21 “Covered Products” means the Solo Product and BASF Products. 
  
 1.22 [*]. 
  
 1.23 “Effective Date” means the date on which AMVAC receives written notice from BASF that there is Resolution. 
  

 Page 3 of 30 

 1.24 “Exclusive” means that, for the duration of the Initial Term and, if
applicable, the Extended Term, the Party granting the right or license in question would neither retain for itself the rights granted to the other Party nor grant such rights to any Person. 
  
 1.25 “Extended Term” shall have the meaning ascribed
to it in Section 10.1. 
  
 1.26 “Field”
means use as a [*] only. 
  
 1.27 “Governmental
Authority” means any governmental department, commission, board, bureau, agency, court or other instrumentality of any supranational organization of sovereign states, country, state, province, territory, commonwealth, municipality or other
political subdivision thereof. 
  
 1.28 “Initial
Registrations” means (i) the initial Registration in the US for the Compound TGAI or the Solo Product, whichever occurs first and (ii) the initial Registration in Canada for the Compound TGAI or the Solo Product, whichever occurs first.

  
 1.29 “Initial Term” shall have the
meaning ascribed to it in Section 10.1. 
  
 1.30
“Invention” means any and all developments, modifications, discoveries, and inventions, whether patentable or not, made by or on behalf of AMVAC with respect to, related to, derived from, based on, or comprising in any way,
whether directly or indirectly and whether in whole or in part, the [*] Patent or any BASF Patent, BASF Know-How, Information and Data, Additional Data, Additional Initial Registration Work Data, Joint Additional Initial Registration Work Data, New
Study Data, or Joint New Study Data. 
  
 1.31
“[*]” means [*], a company organized under the laws of [*]. 
  
 1.32 “Non-Exclusive” means that, for the duration of the Initial Term and, if applicable, the Extended Term, the Party granting the right or license in question retains for itself the rights
granted to the other Party as well as the right to grant such rights to any Person. 
  
 1.33 “Other Product” means any [*] coformulation, other than a BASF Product, which contains the Compound TGAI and [*], none of which are proprietary to BASF and (i) for the US, has [*] use rate
or such lower use rate to which BASF consents in writing or (ii) for Canada, has [*] use rate or such lower use rate to which BASF consents in writing. 
  
 1.34 “[*] Products Royalty” shall have the meaning ascribed to it in Section 5.6(B). 
  
 1.35 “Person” means, other than a Party, any
individual, corporation, partnership, association, trust or other entity or organization including, without limitation, any Governmental Authority. 
  
 1.36 “PMRA” means Canada’s Pest Management Regulatory Agency. 
  
 1.37 “Products” means BASF Products, the Solo Product, and Other Products. 
  
 1.38 “Register” or “Registration”
means the Initial Registrations and any registration, registration change, or re-registration as well as the maintenance or renewal of any such registration or re-registration which is required by EPA or PMRA in order to offer for sale, sell,
promote, and/or distribute in the US or Canada, respectively, the Compound TGAI or any Product for use in the Field only. 
  
 1.39 “Registration Fees” means the so-called “fee for service” fees that the EPA and/or PMRA charges to either Party in
connection with any Registration of the Compound TGAI and/or any Product plus interest, if any. 
  
 1.40 “Resolution” means [*]. 
  

 Page 4 of 30 

 1.41 [*]. 
  

1.42 “Shared Gross Profit for [*] Products” shall have the meaning ascribed to in Section 5.6(A). 
  
 1.43 “Solo Product” means that post-emergent corn
herbicide formulation which contains the Compound TGAI as the sole herbicidal active ingredient, meets the Specifications, and (i) for the US, has [*] use rate or such lower use rate to which BASF consents in writing or (ii) for Canada, has [*] use
rate or such lower use rate to which BASF consents in writing. 
  
 1.44 “Specifications” means (i) the specifications for Compound TGAI and (ii) the specifications for the Solo Product, as the context dictates, which are set forth in Schedule 1.44. 
  
 1.45 “Term” shall have the meaning ascribed to it in
Section 10.1. 
  
 Unless otherwise indicated to the contrary in
this Agreement by the context or use thereof: (i) words importing the masculine gender shall also include the feminine and neutral genders, and vice versa; and (ii) words importing the singular shall also include the plural, and vice versa.

  
 ARTICLE II 
 LICENSES 
  
 2.1 Grants. 
  
 A. AMVAC Development Work, Registrations and Formulations. For the duration of the [*] and subject to the terms and conditions of
this Agreement, BASF grants to AMVAC a (i) [*] sublicense, without the right to grant a sublicense to any Person, under the [*] Patent and (ii) [*] license, without the right to grant a sublicense to any Person, to use and Cite to the BASF Know-How,
Information and Data, and under the BASF Patents for the exclusive purposes of AMVAC: 
  
 (a) undertaking Additional Development Work, Additional Initial Registration Work (as that term is defined in Section 2.4(A)(i)), Joint
Additional Initial Registration Work, New Studies (as that term is defined in Section 2.4(A)(ii)), and Joint New Studies (collectively, “AMVAC Development Work”) in the Field in the Territory; 
  
 (b) obtaining in AMVAC’s name Registrations ;and

  
 (c) formulating or having formulated, in the
Territory only, Products. 
  
 B.
Commercialization. For the duration of the [*] and subject to the terms and conditions of this Agreement, BASF grants to AMVAC a (i) [*] sublicense, without the right to grant a sublicense to any Person, under the [*] Patent and (ii) [*]
license, without the right to grant a sublicense to any Person, to use and Cite to the BASF Know-How, Information and Data and under the BASF Patents for the exclusive purpose of AMVAC offering for sale, selling, promoting, and distributing Products
in the Field in the Territory only. In consideration of the Exclusive nature of the license granted to AMVAC in this Section 2.1(B) (but subject to the provisions of Schedule 10.1) and the obligations assumed by AMVAC under the LOI and
pursuant to Section 2.4(A)(i), (a) BASF agrees that it shall not offer for sale, sell, promote, or distribute in the Territory prior to [*] any product containing any [*] active ingredient which is proprietary to BASF and, as of the Effective Date,
not registered by BASF for use in the Field, provided that the foregoing obligation shall not apply to any Acquired Product (as hereinafter defined) and (b) AMVAC agrees that it shall not offer for sale, sell, promote, or distribute in the Territory
during the [*] any product including, without limitation, any Acquired Product, but excluding Products, containing any [*] active ingredient which product is, as of the Effective Date, neither registered nor promoted, distributed, or marketed by
AMVAC for use in the Field; provided, however, that if an Acquired Product becomes part of the AMVAC product portfolio during the Term, AMVAC shall have the right, but not the obligation, to dispose of such Acquired Product to a non-

  

 Page 5 of 30 

 
Affiliate Person within six (6) months of AMVAC’s acquisition of the Acquired Product in question. For purposes of this Section 2.1(B),
“Acquired Product” means any product acquired by BASF or AMVAC, as the case may be, and/or any Affiliate thereof after the Effective Date, whether acquired as a result of a merger, reorganization, purchase of stock or assets, or by
virtue of a licensing or other similar transaction, in each case with a bona fide, non-Affiliate Person. 
  
 2.2 [Intentionally Omitted]. 
  
 2.3 No Additional License. For the avoidance of doubt, AMVAC acknowledges and agrees that all rights in and to the BASF Study Data is or shall vest
exclusively in BASF or its designee(s) and that except for the licenses granted to AMVAC under Section 2.1, no right or license, either express or implied, under the BASF Study Data or any patent, copyright, trade secret, know-how or other
intellectual property right of BASF or any Affiliate thereof is granted to AMVAC under this Agreement or otherwise. 
  
 2.4 Responsibility, Cost and Ownership. 
  
 A. Development Work and Registrations. 
  
 (i) Additional Development Work, Additional Initial Registration Work, Joint Additional Initial Registration Work, and
Registrations. During the Term, AMVAC shall undertake diligently and shall have exclusive responsibility for (i) obtaining and maintaining all Registrations within the Territory at its sole cost and expense, subject to the remaining
provisions of this Section 2.4(A), and (ii) performing all Additional Development Work at its sole cost and expense. Notwithstanding the foregoing, if the cost to obtain the Initial Registrations in both countries of the Territory exceeds, in the
aggregate, [*] (such actual, out-of-pocket, costs for the Initial Registrations exceeding [*] referred to herein as the “Additional Initial Registration Costs”), such Additional Development Work necessary to obtain the Initial
Registrations shall be deemed “Additional Initial Registration Work” or “AIRW”. AMVAC shall promptly notify BASF of all Additional Initial Registration Work and if the Parties decide to jointly conduct such AIRW
(“Joint Additional Initial Registration Work” or “JAIRW”), the Parties will (x) cooperate in conducting the JAIRW, (y) share equally the Additional Initial Registration Costs for such JAIRW, (z) jointly own the
results of such JAIRW (the “Joint Additional Initial Registration Work Data” or “JAIRW Data”) but, for the duration of the Term, use such JAIRW Data subject to the terms and conditions of this Agreement;
provided, however, that payment by BASF of its [*] of the aggregated Additional Initial Registration Costs for such JAIRW shall be made via deduction, of an amount equal to [*] of such aggregated Additional Initial Registration Costs,
from the Shared Gross Profit for [*] Products and [*] Products Royalty for [*] during which a Shared Gross Profit for [*] Products and/or [*] Products Royalty occurs (the “Additional Initial Registration Costs Deduction” or
“AIRCD”); and provided, further, that in the event that the aggregate amount of the Shared Gross Profit for [*] Products and [*] Products Royalty for [*] is insufficient to cover the AIRCD in question, the Parties
agree that the remaining amount of such AIRCD shall be made via deduction of an amount equal to [*] thereof from the Shared Gross Profit for [*] Products and [*] Products Royalty for each of the immediately [*] during which a Shared Gross Profit for
[*] Products and/or [*] Products Royalty occurs; and provided, finally, that if after such [*] period BASF still owes any portion of the AIRCD in question it shall make a lump sum payment to AMVAC equal to [*]. If BASF decides not to
participate in the cost and/ or performance of any given AIRW, AMVAC agrees to use commercially reasonable efforts to conduct such AIRW (and to promptly advise BASF if AMVAC intends to not conduct the AIRW in question) and AMVAC shall have the
right, subject to the terms and conditions of this Agreement including, without limitation, the provisions of this Section 2.4(A) and Section 10.2(A), to conduct such AIRW at its sole cost and expense and, subject to the provisions of this Section
2.4(A), the applicable provisions of Section 10.3, BASF’s proprietary rights in and to the BASF Patents, BASF Know-How, Information and Data, and any other intellectual property of BASF or any of its Affiliates, all rights in and to the results
of such AIRW (the “Additional Initial Registration Work Data” or “AIRW Data”) shall vest exclusively in AMVAC or its designee(s). AMVAC shall have the right, subject to the terms and conditions of this Agreement
including, without limitation, the provisions 

  

 Page 6 of 30 

 
of this Section 2.4(A), to use such AIRW Data in the Field in the Territory. Notwithstanding the licenses granted to BASF with respect to AIRW Data pursuant
to Section 2.4(C), if subsequent to BASF’s decision to not fund any given Additional Initial Registration Work BASF desires to become a joint owner of any AIRW Data, it shall reimburse AMVAC in accordance with the provisions of the Data
Depreciation Formula and, upon making the payment calculated according to such Data Depreciation Formula, (i) the AIRW Data in question shall be deemed JAIRW Data, (ii) the Additional Initial Registration Work from which the JAIRW Data in question
resulted shall be deemed JAIRW, and (iii) AMVAC shall execute such documents as are reasonably required under Applicable Law to vest in BASF its ownership interest, rights, and title in and to the JAIRW Data in question. For the avoidance of doubt,
the Parties agree that the Registration Fees shall not count toward the Additional Initial Registration Costs. Subject to the provisions of this Section 2.4(A), the applicable provisions of Sections 10.1 and 10.3, BASF’s proprietary rights in
and to the BASF Patents, BASF Know-How, Information and Data, and any other intellectual property of BASF or any of its Affiliates, all rights in and to Additional Data and Registrations shall vest exclusively in AMVAC or its designee(s).

  
 (ii) New Studies and [*]
New Studies. If any Governmental Authority in the Territory requests that AMVAC, or if AMVAC is required by any Governmental Authority in the Territory to, conduct any new or additional studies to permit Registration (other than the
Initial Registrations) or maintain any Registration (including the Initial Registrations) of Compound TGAI or any Products (each such new or additional study, a “New Study”), AMVAC shall promptly provide notice thereof to BASF. If
any Governmental Authority requests that BASF, or if BASF is required by any Governmental Authority to, conduct any study related to the Compound BASF may, but is not obligated to, notify AMVAC of the same and offer it an opportunity to participate
in the cost and/or performance thereof as hereinafter provided (each such study, a “BASF New Study”). If the Parties decide to [*] conduct any New Study or BASF New Study (each, a “[*] New Study”), the Parties will
(i) cooperate in conducting the [*] New Study, (ii) share [*] the total actual out-of-pocket costs therefor, (iii) [*] own the results of such [*] New Study (the “[*] New Study Data”) but, for the duration of the Term, use such [*]
Study Data subject to the terms and conditions of this Agreement. If BASF decides not to participate in the cost and/or performance of any given New Study, AMVAC agrees to use commercially reasonable efforts to conduct such New Study (and to
promptly advise BASF if AMVAC intends to not conduct the New Study in question) and AMVAC shall have the right, subject to the terms and conditions of this Agreement including, without limitation, the provisions of this Section 2.4(A) and Section
10.2(A), to conduct such New Study [*] and, subject to the provisions of this Section 2.4(A), the applicable provisions of Section 10.3, BASF’s proprietary rights in and to the BASF Patents, BASF Know-How, Information and Data, and any other
intellectual property of BASF or any of its Affiliates, all rights in and to the results of such New Study (the “New Study Data”) shall vest [*] in AMVAC or its designee(s). AMVAC shall have the right, subject to the terms and
conditions of this Agreement including, without limitation, the provisions of this Section 2.4(A), to use such New Study Data in the Field in the Territory. Notwithstanding the licenses granted to BASF with respect to New Study Data pursuant to
Section 2.4(C), if subsequent to BASF’s decision to not fund any given New Study BASF desires to become a [*] of any New Study Data, it shall reimburse AMVAC in accordance with the provisions of the Data Depreciation Formula and, upon making
the payment calculated according to such Data Depreciation Formula, (i) the New Study Data in question shall be deemed [*] New Study Data, (ii) the New Study from which the New Study Data in question resulted shall be deemed a [*] New Study, and
(iii) AMVAC shall execute such documents as are reasonably required under Applicable Law to vest in BASF its ownership interest, rights, and title in and to the [*] New Study Data. For the avoidance of doubt, if AMVAC decides not to participate in
the performance of any given BASF New Study, BASF shall have the right to conduct such BASF New Study [*] and all rights in and to the results of such BASF New Study (the “BASF New Study Data”) shall vest [*] in BASF or its
designee(s). Subsequent to AMVAC’s decision to not fund any given BASF New Study, AMVAC may become a [*] of any BASF New Study Data upon AMVAC reimbursing BASF in an amount to be mutually agreed for such BASF New Study, provided that such
amount shall in no event exceed [*] of BASF’s actual out-of-pocket costs to conduct such BASF New Study. Upon AMVAC’s payment of such mutually agreed 

  

 Page 7 of 30 

 
amount, (i) the BASF New Study Data in question shall be deemed [*] New Study Data, (ii) the BASF New Study from which the BASF New Study Data in question
resulted shall be deemed a [*] New Study, and (iii) BASF shall execute such documents as are reasonably required under Applicable Law to vest in AMVAC its ownership interest, rights, and title in and to the [*] New Study Data. 
  
 (iii) AMVAC Data Obligations. The Parties
acknowledge and agree that: 
  
 (a)
notwithstanding the provisions of Section 2.4(A)(i) and (ii), AMVAC shall not have the right to undertake any development work with respect to the Compound TGAI or any Product including, without limitation, AMVAC Development Work unless (1)
Registration of the Compound TGAI or such Product will not be granted or continued by EPA or PMRA if the AMVAC Development Work in question is not performed or (2) AMVAC obtains the prior written consent of BASF, not to be unreasonably withheld or
delayed, if such AMVAC Development Work would not meet the criteria set forth in the preceding clause (1); 
  
 (b) notwithstanding the provisions of Section 2.4(A)(i) and (ii), AMVAC shall obtain BASF’s prior written approval, not to be
unreasonably withheld or delayed, of each protocol for AMVAC Development Work prior to commencement thereof; 
  
 (c) AMVAC shall not withdraw any Additional Data, Additional Initial Registration Work Data, Joint Additional Initial Registration Work
Data, Joint New Study Data, or New Study Data (collectively, the “AMVAC Data”) once the same is submitted to EPA and/or PMRA without the prior written consent of BASF; 
  
 (d) BASF shall have the right to review any and all AMVAC Data prior to AMVAC’s submission thereof to
EPA, PMRA, or any other Governmental Authority in or outside the Territory upon request to AMVAC, and 
  
 (e) BASF shall have the right to review any and all correspondence by or on behalf of AMVAC with, and responses by or on behalf of AMVAC
to any inquiry of, EPA, PMRA and any other Governmental Authority in or outside the Territory with respect to the Compound TGAI or any Product prior to AMVAC’s submission of such correspondence or response thereto. 
  
 B. Initial Registrations. AMVAC agrees to use all commercially
reasonable efforts to obtain the Initial Registrations by [*]. 
  
 C. BASF’s Access to Additional Data, Additional Initial Registration Work Data, and New Study Data. 
  
 (i) Outside the Territory. AMVAC hereby grants to BASF a [*] (subject to the provisions of this Agreement), [*] license,
without the right to grant any sublicense other than as expressly set forth in clause (iii) below, in and outside the Field, outside the Territory, to use and Cite to the Additional Data, Additional Initial Registration Work Data, and New Study Data
for the [*] purposes of: (a) undertaking development work with respect to the Compound, technical grade(s) of active ingredient of the Compound, and products containing any such technical grade(s) of active ingredient of the Compound as an active
ingredient; (b) obtaining registrations for the aforesaid technical grade(s) of active ingredient and/or aforesaid products; (c) formulating or having formulated the aforesaid products; and (d) offering for sale, selling, promoting, and
distributing, directly or indirectly, such products. 
  
 (ii) In the Territory. AMVAC hereby grants to BASF a [*] (subject to the provisions of this Agreement), [*] license, without the right to grant any sublicense other than as expressly set forth in clause (iii) below, in the
Territory, to use and Cite to the Additional Data, Additional Initial Registration Work Data, and New Study Data for the exclusive purposes of: (a) undertaking 

  

 Page 8 of 30 

 
development work with respect to the Compound, technical grade(s) of active ingredient of the Compound, and products containing any such technical grade(s)
of active ingredient of the Compound as an active ingredient; (b) obtaining registrations for the aforesaid technical grade(s) of active ingredient and/or aforesaid products; (c) formulating or having formulated the aforesaid products; and (d)
offering for sale, selling, promoting, and distributing, directly or indirectly, such products outside the Field. 
  
 (iii) Sublicenses. Under the license granted to it in Section 2.4(C)(i), BASF shall have the right to grant a sublicense,
but without the right to further license or sublicense, (a) to any of its Affiliates conducting business in a country in which BASF desires to exercise any of the rights granted to it under the license in question, provided that BASF’s right to
grant any such sublicense shall be limited to one Affiliate per country and (b) in [*] only, to [*]. Under the license granted to it in Section 2.4(C)(ii), BASF shall have the right to grant a sublicense, but without the right to further license or
sublicense, to any [*] for purposes of such [*] exercising in the [*], respectively, any of the rights granted to BASF under the license in question. 
  
 (iv) Access Fee. In consideration of the licenses granted to BASF pursuant to Sections 2.4(C)(i) and (ii), BASF agrees to
pay to AMVAC, during the Term, subject to the applicable provisions of Article X and Schedule 10.1, but in no event after expiration of the Term, certain Access Fees. For the avoidance of doubt, the licenses granted under Sections 2.4(C)(i) and (ii)
shall survive expiration and termination, other than termination by AMVAC pursuant to Section 10.2(A) for breach by BASF, of this Agreement except that such licenses shall be [*] at such time; provided, however, that in the case of
termination of this Agreement by AMVAC pursuant to Section 10.2(A) for breach by BASF, BASF shall have the option, but not the obligation, to become a [*] of any or all Additional Data, Additional Initial Registration Work Data, and New Study Data
by compensating AMVAC in accordance with the provisions of the Data Compensation Formula, at which time the applicable provisions of Section 2.4 shall apply with respect to such joint ownership. 
  
 2.5 [*] Effects. If during or after the Term a Party observes
or is advised by any Person of any actual or potential [*] effect of the Compound TGAI or any Product including, without limitation, any [*] (for purposes of this Section 2.5, an “Observing Party”), such Observing Party shall notify
the other Party in accordance with the provisions of Section 13.3 no later than [*] following the Observing Party’s receipt of such information; provided, however, that [*], notification by the Observing Party to the other Party
shall be immediate. All notices required hereunder shall include a detailed description of the [*] effects observed including, without limitation, the nature of the study or incident and the time and place of the occurrence. The provisions of this
Section 2.5 will survive the termination or expiration of this Agreement for a period of [*]. 
  
 2.6 Reporting. No later than each January 1 and June 1 during the Term, AMVAC shall submit to BASF a written status report detailing the progress of and schedule for the Additional Development Work and the
timetable for Registrations in the Territory. 
  
 2.7 BASF
Employee Assistance. [*], the BASF employees identified in Schedule 2.7 shall be reasonably available to answer technical and biological questions AMVAC may have with respect to the Compound; provided, however, that such
availability is at BASF’s sole and complete discretion, not to be unreasonably withheld or delayed, and at times and dates convenient to the business of BASF. 
  
 ARTICLE III 
 REGISTRATION FEES 
  
 To avoid adverse
developments in the Registration process(es) for the Compound TGAI or any Product in the Territory, AMVAC hereby agrees that if the due date for any Registration Fee(s) occurs after the Effective Date, AMVAC shall pay any and all such Registration
Fees that BASF is required by the EPA and/or PMRA to remit with respect to such Registration process(es). Upon the Effective Date, BASF shall execute such documents as are reasonably required under Applicable Law to transfer the applications for
Registrations to AMVAC. 
  

 Page 9 of 30 

 ARTICLE IV 
 COMMERCIALIZATION OF THE COMPOUND TGAI AND PRODUCTS 
  
 4.1 Commercialization Rights. Pursuant to Section 2.1(B) and subject to the terms and conditions of this Agreement, AMVAC shall have an [*] right
to offer for sale, sell, promote, and distribute the Compound TGAI and Products in the Field in the Territory for the duration of the [*]. 
  
 4.2 Compensation. In consideration for the rights and licenses granted to AMVAC under this Agreement, AMVAC agrees to make the payments described
in Section 4.3 in the installments described in, and subject to the terms and conditions of, such Section 4.3. 
  
 4.3 License Payments. AMVAC agrees to compensate BASF as follows: 
  
 A. Lump Sum Payment. AMVAC shall make a one-time, lump sum payment of [*] to BASF [*]
within [*]. Such [*] payment shall be made in [*] via wire transfer to an account specified by BASF. Upon receipt of the [*] payment, BASF shall provide a complete copy of the BASF Know-How, Information and Data to AMVAC. 

 
 B. Fees. The Parties agree that the fee for the
rights and licenses granted to AMVAC under this Agreement shall be included in the Compound Prices specified in Section 5.5. 
  
 C. Profit Sharing and Royalties. BASF shall share in AMVAC’s profits on, and be entitled to receive royalties from,
AMVAC’s sales of Products in accordance with the provisions of Section 5.6. 
  
 4.4 Marketing. 
  
 A. Commercial Launch. AMVAC agrees to use all commercially reasonable efforts to commence commercial launch of the Products in the Territory by [*]. 
  
 B. Trademarks. Subject to the provisions of this
Section 4.4(B), AMVAC may advertise, promote, market, sell and distribute Products under any trademark, trade name and trade dress of its own choosing (collectively, the “AMVAC Trademarks”); provided, however, that AMVAC shall not
associate any AMVAC Trademark with any trademark used by or registered to BASF or any Affiliate thereof (each, a “BASF Trademark”). AMVAC agrees not to claim or to assert any right of ownership in or to any BASF Trademark or the goodwill
associated therewith. AMVAC further agrees not to take any action which may destroy, damage or impair in any way the ownership or rights of BASF or any Affiliate thereof in or to any BASF Trademark. AMVAC shall not register, either directly or
indirectly, in its own name or on behalf of any other Person, any trademark identical, or confusingly similar, to any BASF Trademark. AMVAC shall not adopt, use, own, or acquire any BASF Trademark, or any mark, name or trade dress confusingly
similar thereto. BASF agrees not to claim or to assert any right of ownership in or to any AMVAC Trademark or the goodwill associated therewith. BASF further agrees not to take any action which may destroy, damage or impair in any way the ownership
or rights of AMVAC or any Affiliate thereof in or to any AMVAC Trademark. BASF shall not register, either directly or indirectly, in its own name or on behalf of any other Person, any trademark identical, or confusingly similar, to any AMVAC
Trademark. BASF shall not adopt, use, own, or acquire any AMVAC Trademark, or any mark, name or trade dress confusingly similar thereto. Nothing in this Section 4.4(B) is intended to limit either Party’s rights under applicable trademark law.

  
 4.5 [*]. [*], BASF agrees to [*] with AMVAC concerning
[*] BASF granting AMVAC the right(s) and/or license(s) necessary for AMVAC to register and offer for sale, sell, promote, and distribute the Compound TGAI and Products in the Field in [*]. 
  

 Page 10 of 30 

 ARTICLE V 
 MANUFACTURE, SUPPLY AND PURCHASE OF THE COMPOUND TGAI 
  
 5.1 Manufacture of the Compound TGAI. During the Term, BASF retains the exclusive rights to manufacture and/or have manufactured the Compound TGAI
for sale to AMVAC. 
  
 5.2 Exclusive Source. During the
Term, AMVAC shall purchase one hundred percent (100%) of its requirements for the Compound TGAI from BASF or an Affiliate thereof exclusively pursuant to the terms and conditions of this Agreement. 
  
 5.3 Minimum Purchase Requirement. If, during the period commencing
with the Contract Year during which Commercialization occurs and ending with the expiration of the [*] Contract Year thereto, AMVAC does not purchase the Cumulative Minimum Volume (as that term is hereinafter defined), then BASF shall have the
right, and without the need for any further action, to convert the license granted to AMVAC under Section 2.1(B) from Exclusive to Non-Exclusive and AMVAC shall do all commercially reasonable things necessary to enable BASF to use and Cite, [*] to
AMVAC’s Registrations and any and all AMVAC Data in support thereof. For purposes of this Agreement, “Cumulative Minimum Volume” means [*] of one hundred percent (100%) Compound TGAI. Starting with the [*] Contract Year [*] to
the Contract Year during which Commercialization occurs, BASF shall have the right to terminate this Agreement upon [*] prior written notice and the provisions of Section 10.3(B) shall apply if AMVAC does not purchase an aggregate of [*] of one
hundred percent (100%) Compound TGAI in any [*] Contract Years. 
  
 5.4 Forecasts and Ordering. 
  
 A. If Registration/Commercialization is Expected by [*]. 
  
 (i) [*] Contract Year During Which Commercialization is Expected to Occur. If AMVAC expects to obtain an Initial Registration and to commence Commercialization by [*], then for the [*]
Contract Year during which Commercialization is expected to occur AMVAC shall: 
  
 (a) submit its [*] forecast for Products to BASF no later than [*]; 
  
 (b) place its [*] order for Compound TGAI and/or Products no later than [*], which [*] order shall be
within [*] of the aforesaid [*] forecast; and 
  
 (c) take delivery, in accordance with the provisions of Section 5.10, of Compound TGAI and/or Products during [*], or such other mutually agreed date. 
  

(ii) [*] Contract Year Following Commercialization. If AMVAC expects to obtain an Initial Registration and
to commence Commercialization by [*], then for the [*] Contract Year following the Contract Year during which Commercialization occurs AMVAC shall: 
  
 (a) submit its [*] forecast for Products to BASF no later than [*]; and 
  
 (b) place its [*] order for Compound TGAI and/or Products no later than [*], which [*] order shall be
within [*] of the aforesaid [*] forecast and shall specify the desired delivery date and US port of entry. 
  
 (iii) [*] Contract Years Following Commercialization. If AMVAC expects to obtain an Initial Registration and
to commence Commercialization by [*], then for the [*] Contract Years following the Contract Year during which Commercialization occurs AMVAC shall: 
  
 (a) submit its [*] forecast for Products to BASF no later than [*] of each such prior Contract Year (e.g., the first such forecast would
be due [*] for the [*] season); and 
  

 Page 11 of 30 

 (b) place its [*] order for Compound TGAI and/or Products no later than [*] of each such
prior Contract Year, which [*] order shall be within [*] of the aforesaid [*] forecast and shall specify the desired delivery date and US port of entry (e.g., the first such forecast would be due [*] for the [*] season). 
  
 B. If Registration/Commercialization is Expected Later
Than [*]. 
  
 (i) [*]
Contract Year During Which Commercialization is Expected to Occur. If AMVAC expects to obtain an Initial Registration and to commence Commercialization after [*], then for the [*] Contract Year during which Commercialization is
expected to occur AMVAC shall: 
  
 (a) submit
its [*] forecast for Products to BASF no later than [*]; 
  
 (b) place its [*] order for Compound TGAI and/or Products no later than [*], which [*] order shall be within [*] of the aforesaid [*] forecast; 
  
 (c) take delivery, in accordance with the provisions of Section 5.10, of Compound TGAI and/or Products
during [*] or such other mutually agreed date; and 
  
 (d) if necessary, submit a [*] order for additional Compound TGAI and/or Products no later than [*] and specify in such order the desired delivery date and US port of entry. 
  
 (ii) [*] Contract Year Following Commercialization. If AMVAC expects to obtain
an Initial Registration and to commence Commercialization after [*], then for the [*] Contract Year following the Contract Year during which Commercialization occurs AMVAC shall: 
  
 (a) submit its [*] forecast for Products to BASF no later than [*]; and 
  
 (b) place its [*] order for Compound TGAI and/or Products
no later than [*], which [*] order shall be within [*] of the aforesaid [*] forecast and shall specify the desired delivery date and US port of entry. 
  
 (iii) [*] Contract Years Following Commercialization. If AMVAC expects to obtain an Initial Registration and
to commence Commercialization after [*], then for the [*] Contract Years following the Contract Year during which Commercialization occurs AMVAC shall: 
  
 (a) submit its [*] forecast for Products to BASF no later than [*] of each such Contract Year; and 
  
 (b) place its [*] order for Compound TGAI and/or Products
no later than [*] of each such Contract Year, which [*] order shall be within [*] of the aforesaid [*] forecast and shall specify the desired delivery date and US port of entry. 
  
 C. Rolling Forecasts. Commencing no later than [*] of the Contract Year during which
Commercialization occurs and beginning with each calendar quarter thereafter during the Term, AMVAC shall submit a written, [*] rolling forecast of its requirements for the Compound TGAI (i) on a [*] basis for the [*] Contract Years following the
Contract Year in which Commercialization occurs and (ii) on a [*] basis for the [*] Contract Years following the Contract Year in which Commercialization occurs. 
  
 5.5 Price. 
  
 A. [*] Contract Year During Which Commercialization Occurs and the [*] Contract Years. For the [*] Contract Year
during which Commercialization occurs and for the [*] Contract Years, the Compound Price shall be: 
  
 (i) For the [*] during which Commercialization occurs, [*] of one hundred percent (100%) Compound TGAI [*]; 
  

 Page 12 of 30 

 (ii) For the [*] following the Contract Year during which Commercialization occurs, [*]
of one hundred percent (100%) Compound TGAI [*]; and 
  
 (iii) For the [*] following the Contract Year during which Commercialization occurs, [*] of one hundred percent (100%) Compound TGAI [*]. 
  
 B. [*] Contract Years Following the Contract Year During Which Commercialization Occurs When AMVAC’s Orders Equal or Exceed the
Minimum Volume. For purposes of this Section 5.5(B) and Section 5.5(C), “Minimum Volume” means [*] of one hundred percent (100%) Compound TGAI. Provided that in the [*] Contract Year following the Contract Year during which
Commercialization occurs AMVAC orders an amount of Compound TGAI which is equal to or exceeds the Minimum Volume, the Compound Price shall be equal to [*]. 
  
 C. [*] Contract Years Following the Contract Year During Which Commercialization Occurs When AMVAC Orders
Less than the Minimum Volume. If in the [*] Contract Year following the Contract Year during which Commercialization occurs AMVAC orders an amount of Compound TGAI which is less than the Minimum Volume, the Compound Price for such year shall be
equal to [*]. 
  
 5.6 Profit Sharing and
Royalties. 
  
 A. [*] Products.
In consideration for the licenses granted in Section 2.1 to AMVAC with respect to [*] Products, for the Contract Year during which Commercialization occurs and each [*] Contract Year during which any [*] Product is sold by AMVAC, BASF and AMVAC
shall share [*] the Shared Gross Profit for [*] Products, subject to the provisions of Section 8.3. No later than each [*] of the Contract Year during which Commercialization occurs and each [*] Contract Year, AMVAC shall prepare and provide to BASF
an interim report which reasonably estimates the expected Shared Gross Profit for [*] Products for the then-current Contract Year. AMVAC shall reconcile the Shared Gross Profit for [*] Products for the Contract Year in question and remit to BASF its
[*] share thereof in [*] via wire transfer to an account specified by BASF no later than [*] of the Contract Year during which the sales of the [*] Products leading to the Shared Gross Profit for [*] Products in question were made, such earnings to
be determined by AMVAC in accordance with generally accepted accounting principles for the US. For purposes of this Agreement, “Shared Gross Profit for [*] Products” for any given Contract Year means [*]. 
  
 B. [*] Products. In consideration for the licenses
granted in Section 2.1 to AMVAC with respect to [*] Products, for the Contract Year during which Commercialization occurs and each [*] Contract Year during which any [*] Product is sold by AMVAC, it shall pay to BASF (i) a royalty in an amount equal
to [*] contained, in the aggregate, in the [*] Products sold by AMVAC in the US during the Contract Year in question (the “US Royalty”) and (ii) a royalty in an amount equal to [*] contained, in the aggregate, in the [*] Products
sold by AMVAC in Canada during the Contract Year in question (the “Canadian Royalty” and, together with the US Royalty, the “[*] Products Royalty”), subject to the provisions of Section 8.3. No later than
each [*] of the Contract Year during which Commercialization occurs and each [*] Contract Year, AMVAC shall prepare and provide to BASF an interim report which reasonably estimates the expected [*] Products Royalty for the then-current Contract
Year. AMVAC shall reconcile the [*] Products Royalty for the Contract Year in question and remit to BASF payment therefor in [*] via wire transfer to an account specified by BASF no later than [*] of the Contract Year during which the sales of the
[*] Products leading to the [*] Products Royalty payment in question were made, such earnings to be determined by AMVAC in accordance with generally accepted accounting principles for the US. 
  

 Page 13 of 30 

 5.7 Audit Rights. 
  
 A. AMVAC’s Rights. If in the [*] Contract Year following the Contract Year during which
Commercialization occurs, AMVAC orders more than the Minimum Volume and it disputes the Compound Price for such Contract Year (the “Disputed Compound Price”), the Parties shall mutually agree on the appointment of a recognized firm
of international public accountants to review (as “review” is commonly understood and used in Generally Accepted Auditing Standards (“GAAS”)) and certify BASF’s statement of the Disputed Compound Price in question in
accordance with GAAS. AMVAC will have [*] after its receipt of each invoice from BASF for the Compound TGAI to provide BASF with any notice of the Disputed Compound Price in question (the “Compound Price Review Period”). Upon the
expiration of the Compound Price Review Period, the rights described in this Section 5.7(A) shall likewise expire with respect to such Disputed Compound Price. The cost for any appointment, review, and certification referred to in this Section
5.7(A) shall be borne solely by AMVAC; provided, however, that if the results of a particular review and certification reveal that the Disputed Compound Price is actually higher than the Compound Price should be by more than [*], then
the cost of such review and certification shall be borne solely by BASF. The appointed firm shall either certify in accordance with GAAS that BASF’s statement of the Compound Price in question is correct and advise AMVAC of the same or shall
advise AMVAC that the Compound Price in question was incorrectly calculated by BASF and by how much; provided, however that, other than advising AMVAC of the foregoing information, neither BASF nor the reviewer shall disclose or be
obligated to disclose to AMVAC any information that such reviewer either obtains from BASF or any of its Affiliates or creates on its own with respect to the aforesaid review and certification. 
  
 B. BASF’s Rights. If BASF disputes the [*]
Products Royalty and/or the Shared Gross Profit for [*] Products reported by AMVAC for the Contract Year during which Commercialization occurs or any [*] Contract Year (the “Disputed Amount”), the Parties shall mutually agree on the
appointment of a recognized firm of international public accountants to review (as “review” is commonly understood and used in GAAS) and certify AMVAC’s statement of the Disputed Amount in question in accordance with GAAS during the
Contract Year immediately [*] to the Contract Year during which the sales of the Products leading to the Disputed Amount in question were made (the “Review Period”). Upon the expiration of the Review Period, the rights described in
this Section 5.7(B) shall likewise expire with respect to the Disputed Amount in question. The cost for any such appointment, review, and certification shall be borne solely by BASF; provided, however, that if the results of a
particular review and certification reveal that the Disputed Amount reported by AMVAC is lower than the actual [*] Products Royalty and/or Shared Gross Profit for [*] Products by more than [*], then the cost of such review and certification shall be
borne solely by BASF. The appointed firm shall either certify in accordance with GAAS that AMVAC’s statement of the [*] Products Royalty and/or the Shared Gross Profit for [*] Products in question is correct and advise BASF of the same or shall
advise BASF that the [*] Products Royalty and/or the Shared Gross Profit for [*] Products in question was incorrectly calculated by AMVAC and by how much; provided, however that, other than advising BASF of the foregoing information,
neither AMVAC nor the reviewer shall disclose or be obligated to disclose to BASF any information that such reviewer either obtains from AMVAC or any of its Affiliates or creates on its own with respect to the aforesaid review and certification.

  
 5.8 Payment Terms. 
  
 A. Invoices. For each order of the Compound TGAI
placed by AMVAC, BASF or an Affiliate thereof shall issue an invoice in [*] for which the payment date shall be [*] from the later of (i) the date that the Compound TGAI for which such invoice is issued reaches the US port of entry or (ii) the date
on which AMVAC desired delivery of such Compound TGAI, as communicated to BASF by AMVAC in accordance with the provisions of Section 5.4 (a “Due Date”). Interest at the rate of [*] per annum shall be added to each invoice amount
commencing the first day after the corresponding Due Date therefor if payment is not received by such Due Date and shall accrue until such time as the invoice in question is paid in full, unless AMVAC disputes such invoice in accordance with the
provisions of Section 5.7(A). All invoice payments shall be made in [*] and payable to BASF via wire transfer to an account specified by BASF. 
  

 Page 14 of 30 

 B. No Credits or Deductions. All payments shall be made by AMVAC without deduction
for any exchange, conversion, adjustment charge, taxes, or other similar charges at any time levied or assessed by any Governmental Authority. No credit or allowance for returns will be allowed against outstanding invoices or otherwise, without the
prior written consent of BASF. 
  
 5.9 Packaging and
Labeling. The appropriate packaging and labeling for the Compound TGAI delivered under this Article V shall be mutually agreed by the Parties and consistent with BASF’s then-current export guidelines and all Applicable Laws. 
  
 5.10 Delivery. All Compound TGAI shall be delivered to AMVAC [*] at a
European port to be mutually agreed by the Parties and in accordance with BASF’s then-current export guidelines and consistent with all Applicable Laws. BASF will use all commercially reasonable efforts to meet those delivery dates desired by
AMVAC and communicated to BASF in accordance with the provisions of Section 5.4. 
  
 5.11 Testing. 
  
 A. Testing by BASF. BASF shall perform quality control tests on all Compound TGAI supplied under this Article V in accordance with the methods of analysis set forth in Schedule 5.11(A) (the
“Methods of Analysis”). BASF shall provide to AMVAC a certificate of analysis for each batch of Compound TGAI delivered to AMVAC. 
  
 B. Re-Testing by AMVAC. AMVAC may, in its discretion, re-test Compound TGAI in accordance with the Methods of Analysis. If analysis
of a given batch of Compound TGAI which BASF deems conforming is performed by AMVAC and such batch proves to be nonconforming, AMVAC shall advise BASF of the same and the Parties shall consult with each other in order to resolve the discrepancy in
good faith. If such consultation does not resolve the discrepancy, an independent, reputable laboratory designated by the Parties shall repeat the Methods of Analysis on representative samples from the batch provided by AMVAC and the resulting
determination shall be binding on the Parties. Any batch of Compound TGAI alleged by AMVAC not to meet the Specifications shall be held without use by AMVAC pending the outcome of the independent analysis referred to in this Section 5.11(B). The
costs of the independent laboratory analyses referred to in this Section 5.11(B) shall be borne by AMVAC unless the Compound TGAI in question is determined to not conform to the Specifications, in which case the costs of the independent laboratory
analyses shall be borne by BASF. AMVAC’s sole and exclusive remedy with respect to any Compound TGAI which does not conform ultimately to the Specifications is set forth in Section 5.12(B). 
  
 C. Batch Samples. Samples of each batch of Compound
TGAI shall be retained by BASF for a period of at least [*] from the date of shipment of such batch to AMVAC or such period of time required by Applicable Law of the jurisdiction in which the Compound TGAI in question is manufactured, whichever is
of greater duration. 
  
 5.12 Representations and
Warranties. 
  
 A. Quality and
Specifications. BASF warrants and represents that, upon delivery, each order of Compound TGAI shall conform to the Specifications. 
  
 B. Disclaimer. THE WARRANTY SET FORTH IN SECTION 5.12(A) IS EXPRESSLY IN LIEU OF ALL OTHER WARRANTIES REGARDING THE COMPOUND TGAI
AND ALL SUCH OTHER WARRANTIES AND REPRESENTATIONS OF WHATEVER KIND ARE HEREBY DISCLAIMED BY BASF AND WAIVED BY AMVAC. BASF SHALL HAVE NO LIABILITY TO AMVAC FOR ANY GENERAL, INCIDENTAL, INDIRECT, SPECIAL, PUNITIVE, CONSEQUENTIAL OR LIKE DAMAGES,
HOWSOEVER NAMED, INCLUDING, WITHOUT LIMITATION, LOST PROFITS ARISING OUT OF THE USE, FORMULATION, OR IMPORTATION OF ANY COMPOUND TGAI OR THE PROMOTION, OFFER FOR SALE, SALE OR DISTRIBUTION OF COMPOUND TGAI OR ANY PRODUCT. BASF MAKES NO WARRANTIES,
EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PURPOSE 

  

 Page 15 of 30 

 
WITH RESPECT TO ANY COMPOUND TGAI EXCEPT AS SECTION 5.12(A) EXPRESSLY PROVIDES. For the avoidance of doubt, nothing in this Section 5.12(B) is intended to
limit any of AMVAC’s rights or remedies under the applicable provisions of Articles VII and VIII. 
  
 C. Exclusive Remedy. Subject to the provisions of Section 8.2(iv), BASF’s sole liability for any and all breaches of
BASF’s warranty that each order of Compound TGAI shall conform to the Specifications upon delivery thereof to AMVAC shall be expressly limited to replacing the Compound TGAI which is determined, in accordance with the provisions of Section
5.11(B), to be defective provided that the conditions set forth in Section 5.12(D) are satisfied. For the avoidance of doubt, the Parties acknowledge and agree that the provisions of Section 8.2(vi) shall not apply to any breach of Section
5.12(A). 
  
 D. Claims. Any claim for a
breach of Section 5.12(A) shall be valid only when submitted (i) in writing by AMVAC to BASF within [*] after discovery of the defect but in no event later than [*] after receipt by AMVAC at the US port of entry of the Compound TGAI in question or,
in the case of latent defects, no later than [*] after receipt by AMVAC at the US port of entry of the Compound TGAI in question to AMVAC and (ii) together with the allegedly defective Compound TGAI, if such allegedly defective Compound TGAI is
requested by BASF. No claim of any kind shall be valid with respect to any Compound TGAI which has been altered (including, without limitation, formulated or in the process of being formulated into any Product), neglected, damaged, handled or stored
in any manner which either adversely affects such Compound TGAI or is inconsistent with the terms and conditions of this Agreement, unless the Compound TGAI would have been defective, based on comparative batch samples to which Section 5.11(C)
refers for the Compound TGAI in question, regardless of such alteration, neglect, damage, handling or storage. 
  
 E. Survival. This Section 5.12 shall survive expiration or early termination of this Agreement for a period of [*] thereafter.

  
 5.13 All Sales Final. Subject to the provisions of
Sections 5.12(B), (C), and (D) all sales to AMVAC under this Agreement are final and no Compound TGAI may be returned to BASF without its prior written authorization. 
  
 5.14 Applicable Permits. Each Party shall obtain and thereafter maintain all necessary Applicable Permits pertaining
to the exercise of its rights and performance of its obligations under this Agreement. 
  
 5.15 Allocation of Supply. In the event that a force majeure event referred to in Article XI occurs including, without limitation, if the effect of a force majeure event with respect to Compound TGAI is merely
a reduction, rather than a permanent discontinuance, BASF shall allocate its then-remaining supply of Compound TGAI between BASF, its Affiliates and AMVAC in a proportion corresponding to the requirements of each Party therefor for the then-current
Contract Year, it being acknowledged and agreed that reference to BASF’s requirements herein refers to BASF’s own requirements and the requirements of those Persons with whom BASF is party to a legally enforceable agreement covering the
supply of Compound technical form of active ingredient and/or products containing the same as an active ingredient. 
  
 5.16 Other Active Ingredients. The Parties acknowledge that they may discuss the viability of BASF supplying [*] (other than Compound TGAI)
including, without limitation, [*] (“Other [*]”) for use in BASF Products and Other Products; provided, however, any such arrangement shall be negotiated and, if the Parties mutually agree on the terms and conditions
pursuant to which such Other [*] will be supplied and purchased, such arrangement shall be the subject of a separate written agreement between the Parties. For the avoidance of doubt, the Parties acknowledge and agree that AMVAC shall have the right
to purchase Other [*] from any Person; and provided, further, that AMVAC shall notify BASF of the price and other material supply terms for such Other [*], if AMVAC is legally permitted to so notify BASF. BASF shall have [*] from the
date it receives each such notice to meet the terms offered to AMVAC for the Other [*] in question and, if (i) BASF meets such terms and conditions and (ii)AMVAC’s purchase of such Other [*] from BASF would be at least as favorable to AMVAC
when compared to purchasing such Other [*] from another supplier, AMVAC agrees to purchase such Other [*] from BASF pursuant to a mutually acceptable separate written agreement between the Parties. 
  

 Page 16 of 30 

 ARTICLE VI 
 INTELLECTUAL PROPERTY 
  
 6.1 Inventions. 
  
 A.
Disclosure. AMVAC agrees to disclose all Inventions to BASF promptly and in no event later than [*] of discovery or development thereof. 
  
 B. License. If AMVAC develops an Invention and BASF requests that it be granted a license with respect to such Invention in and/or
outside the Territory, then AMVAC shall grant to BASF: 
  
 (i) a [*] (subject to the provisions of Section 10.3(B)), [*] license, without the right to grant any sublicense except as expressly provided in this Section 6.1(B), to use, have used, practice, have practiced, promote, offer to sell, sell,
and distribute such Invention outside the Territory; and/or 
  
 (ii) a [*] (subject to the proviso below), [*] license, without the right to grant any sublicense except as expressly provided in this Section 6.1(B), to use, have used, practice, have practiced, promote, offer to
sell, sell, and distribute such Invention in the Territory, subject to the express provisions of Section 2.1(B). 
  
 The Parties shall negotiate in good faith and agree on a [*] for the license granted under clause (ii) of this Section 6.1(B); provided,
however, that (i) if AMVAC fails to purchase the Cumulative Minimum Volume pursuant to Section 5.3, then the license granted under Section 6.1(B)(ii) by AMVAC to BASF shall be [*] and (ii) if AMVAC fails to purchase an aggregate amount of at
least [*] of one hundred percent (100%) Compound TGAI in [*] Contract Years then, in addition to any other rights BASF may have under Section 10.3, the license granted under Section 6.1(B)(ii) by AMVAC to BASF shall be [*]. Under the licenses
granted to it in this Section 6.1(B), BASF shall have the right to grant a sublicense, but without the right to grant a further license or sublicense, (a) to any of its Affiliates conducting business in a country in which BASF desires to exercise
any of the rights granted to it under the license in question, provided, that BASF’s right to grant any such sublicense shall be limited to one Affiliate per country and (b) in [*] only, to [*]. 
  
 C. Ownership. All rights and title in and to
Inventions, whether patentable or not, conceived or made by AMVAC as a result of its performance under or in connection with this Agreement shall vest [*] in AMVAC or its designee. 
  
 D. Patents. To the extent AMVAC believes that any Invention is patentable, AMVAC shall use all
commercially reasonable efforts to (i) apply for the corresponding patent protection and all other means of like protection (individually and collectively, “IPR Protection”) in its own name and (ii) undertake all steps necessary to
file, prosecute, maintain, and renew all such IPR Protection, at AMVAC’s own cost and expense. In addition, AMVAC will inform BASF about AMVAC’s intended filing of foreign patent applications. BASF shall be entitled to file patent
applications in additional countries at its own cost and expense. Furthermore, AMVAC shall use all commercially reasonable efforts to seek all available time extensions for such IPR Protection. Notwithstanding the foregoing in this Section 6.1(D),
AMVAC shall have the right, at its discretion, to not pursue all available IPR Protection for a given Invention or abandon any IPR Protection obtained therefor, in which event AMVAC shall promptly notify BASF in writing of such decision, whereupon
BASF or its designee(s) shall have the [*] right with respect to such Invention(s) to file, prosecute, maintain, and renew any and all IPR Protection with respect thereto at BASF’s own cost and expense. If AMVAC decides to not pursue all
available IPR Protection for a given Invention or abandon any IPR Protection obtained therefor, at the written request of BASF all of AMVAC’s right, title, and interest in and to such Invention and attendant IPR Protection shall be transferred
and assigned to BASF or its designee(s). 
  

 Page 17 of 30 

 6.2 Automatic Grants. To the extent that AMVAC undertakes in this Agreement to grant to BASF any
license or right including, without limitation, under Section 6.1(B) (but excluding those grants for which a [*] must be mutually agreed) upon the occurrence or happening of any event or condition (including, by way of example and not limitation,
the conversion of a license from [*] and the conversion of a license from [*]), each such license shall be deemed automatically granted upon the occurrence or happening of such event or condition without the need for any further action to be taken
by either Party or their respective Affiliates, notwithstanding the provisions of Section 13.7. 
  
 6.3 Notification. Each Party agrees to promptly provide to the other Party all information of which it is aware as of the Effective Date, or
becomes aware of during the Term, as such information relates to any patent or intellectual property rights which are or may be pertinent to the performance of this Agreement. 
  
 ARTICLE VII 
 REPRESENTATIONS AND WARRANTIES 
  
 7.1
BASF’s Representations and Warranties. 
  
 A. General. BASF represents and warrants to AMVAC that as of the Effective Date, (i) it has (a) the corporate authority and legal right to grant the licenses set forth in Section 2.1,2.1 and (b) achieved Resolution, (ii) as of the
Effective Date, it (or its Affiliates) has [*] ownership rights in and to the BASF Know-How, Information and Data and that it is neither aware, nor in possession, of any information that the BASF Know-How, Information and Data infringes any patent
or other proprietary right of any Person, (iii) neither it nor any of its Affiliates is a party to any oral or written agreement or understanding with any Person that is either inconsistent with or will in any way limit or conflict with its ability
to fulfill its obligations under this Agreement (and BASF hereby covenants that it shall not, and shall ensure that its Affiliates do not, enter into any such agreement or understanding during the Term), and (iv) the performance by BASF of its
obligations under this Agreement, including, without limitation, the granting of the licenses set forth in Section 2.1, will neither breach the [*] nor infringe the [*] Patent. 
  
 B. BASF Know-How, Information and Data and BASF Patents. BASF makes no warranties or representations
concerning either the BASF Know-How, Information and Data or the BASF Patents other than, as of the Effective Date, (i) BASF is neither aware, nor in possession, of any information that any BASF Know-How, Information and Data or any BASF Patent
infringes any patent or other proprietary right of any Person and (ii) there is no pending, or to BASF’s knowledge any threatened, litigation with respect to any BASF Know-How, Information and Data or any BASF Patent. 
  
 7.2. Disclaimers. THE WARRANTIES SET FORTH IN SECTION 7.1 ARE
EXPRESSLY IN LIEU OF ALL OTHER WARRANTIES REGARDING THE BASF KNOW-HOW, INFORMATION AND DATA AND THE BASF PATENTS AND ALL SUCH OTHER WARRANTIES AND REPRESENTATIONS OF WHATEVER KIND ARE HEREBY DISCLAIMED BY BASF AND WAIVED BY AMVAC. BASF MAKES NO
REPRESENTATION, WHETHER EXPRESS OR IMPLIED, WITH RESPECT TO THE BASF KNOW-HOW, INFORMATION AND DATA AS TO MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, SATISFACTORY RESULTS FROM USE THEREOF OR RELIANCE THEREON, OR OTHERWISE AND BASF SHALL NOT
BE LIABLE TO AMVAC FOR ANY GENERAL, INCIDENTAL, INDIRECT, SPECIAL, PUNITIVE, CONSEQUENTIAL OR LIKE DAMAGES, CLAIMS, LIABILITY, LOSSES, OR EXPENSES, HOWSOEVER NAMED, INCLUDING, WITHOUT LIMITATION, LOST PROFITS ARISING OUT OF THE USE OF OR RELIANCE ON
ANY BASF KNOW-HOW, INFORMATION AND DATA. For the avoidance of doubt, nothing in this Section 7.2 is intended to limit any of AMVAC’s rights or remedies under Section 5.12 and the applicable provisions of Article VIII. 
  
 7.3 AMVAC’s Representations and Warranties. AMVAC
represents and warrants that neither it nor any of its Affiliates is a party to any oral or written agreement or understanding with any Person that is either inconsistent with or will in any way limit or conflict with its ability to fulfill its
obligations under this Agreement (and AMVAC hereby covenants that it shall not, and shall ensure that its Affiliates do not, enter into any such agreement or understanding during the Term). 
  

 Page 18 of 30 

 ARTICLE VIII 
 INDEMNIFICATION 
  
 8.1 Obligations of AMVAC. Without prejudice to any other right or remedy BASF may have under this Agreement or otherwise and subject to the provisions of Section 8.5(A), AMVAC shall indemnify, defend and hold harmless BASF, its
Affiliates and their respective directors, officers, employees and agents (individually, a “BASF Indemnitee”) from and against all damages, losses, liabilities, costs, expenses, claims, demands, suits, penalties and judgments as
well as administrative and judicial orders, including reasonable counsel fees and expenses (individually and collectively, “Costs”) incurred, assessed or sustained by or against any BASF Indemnitee with respect to, resulting from or
arising out of: 
  
 (i) any claim that
AMVAC’s performance of any AMVAC Development Work infringes any proprietary right of any Person; 
  
 (ii) any claim that any AMVAC Data infringes any proprietary right of any Person; 
  
 (iii) any claim that AMVAC’s formulation activities
with respect to, and/or the promotion, offer for sale, sale, or distribution of, any Compound TGAI and/or Product infringes any proprietary right of any Person; 
  
 (iv) any claim with respect to the performance of Compound TGAI and/or any Product sold, transferred, or
distributed by or on behalf of AMVAC; 
  
 (v)
AMVAC’s formulation activities with respect to, and/or the handling, shipping, storage, testing, labeling, promotion, offer for sale, sale, or distribution of, any Compound TGAI (whether used singly or in combination with other substances and
whether used in the form delivered or in an altered form) and/or Product; 
  
 (vi) any breach of this Agreement by AMVAC; and 
  
 (vii) any negligence or willful misconduct by AMVAC in its performance under this Agreement. 
  
 8.2 Obligations of BASF. Without prejudice to any other right or
remedy AMVAC may have under this Agreement or otherwise and subject to the provisions of Section 8.5(A), BASF shall indemnify, defend and hold harmless AMVAC, its Affiliates and their respective directors, officers, employees and agents
(individually, an “AMVAC Indemnitee”) from and against all Costs incurred, assessed or sustained by or against any such AMVAC Indemnitee with respect to, resulting from or arising out of: 
  
 (i) any claim that any Compound TGAI or BASF Know-How,
Information and Data infringes any proprietary right of any Person; 
  
 (ii) subject to the provisions of Section 8.5(B), any claim that any BASF Patent infringes any proprietary right of any Person; 
  

(iii) any claim that BASF’s manufacturing activities with respect to Compound TGAI, including, without limitation, the
manufacturing process used by BASF to produce Compound TGAI supplied under this Agreement, infringes any proprietary right of any Person; 
  
 (iv) subject to the provisions of Section 8.3, any defect in Compound TGAI that could not have been reasonably discovered by AMVAC by
performing the Methods of Analysis on the Compound TGAI in question; 
  
 (v) any claim that BASF’s performance of any Joint Additional Initial Registration Work and/or Joint New Study infringes any proprietary right of any Person; 
  

 Page 19 of 30 

 (vi) any breach of this Agreement by BASF; and 
  
 (vii) any negligence of or willful misconduct by BASF in its
performance under this Agreement. 
  
 8.3 [*]
Claims. The Parties agree that for the Contract Year during which Commercialization occurs and the immediately [*] Contract Years, AMVAC shall have the right to deduct from the [*]and the [*] thereof as an accrual in the event of claims
related to the [*] of Compound TGAI and/or any Product ([*]), which, for the avoidance of doubt, the Parties acknowledge and agree shall be AMVAC’s [*]. Deduction by AMVAC of [*] for the Contract Years in question, whether paid out or not,
shall be made prior to AMVAC’s [*].  
  
 8.4
Notification and Other Procedures. Each of AMVAC and BASF shall provide notice in writing to the other Party immediately upon its knowledge of institution of any and all claims, suits and actions referred to in Section 8.1 or 8.2 (each such
claim, suit or action, a “Third Party Claim”). The indemnifying Party shall defend the indemnified Party against the Third Party Claim, Accordingly, the indemnifying Party shall have the right to select legal counsel of its choosing
provided such counsel is reasonably satisfactory to the indemnified Party. The indemnifying Party shall conduct its defense of any and all Third Party Claims actively and diligently. The indemnified Party shall provide to the indemnifying Party all
information and reasonable assistance necessary to the indemnifying Party in the prosecution of defense of each Third Party Claim. An indemnifying Party shall not consent to the entry of any judgment or enter into any settlement with respect to any
Third Party Claim without first consulting with, and obtaining from, the indemnified Party its consent, which shall not be unreasonably withheld or delayed. The indemnified Party shall not consent to the entry of any judgment or enter into any
settlement with respect to any Third Party Claim without first consulting with, and obtaining from, the indemnifying Party its consent, which shall not be unreasonably withheld or delayed. 
  
 8.5 Limitations. 
  
 A. BASF Indemnitees and AMVAC Indemnitees. Subject to
the exception with respect to the [*] Patent set forth in Section 8.6, in no event shall (i) BASF be liable under this Article VIII to any AMVAC Indemnitee for any general, incidental, indirect, special, punitive or consequential damages including,
without limitation, lost profits thereof or (ii) AMVAC be liable under this Article VIII to any BASF Indemnitee for any general, incidental, indirect, special, punitive or consequential damages including, without limitation, lost profits thereof.

  
 B. Blocking Patents. AMVAC shall
undertake all commercially reasonable steps to ensure that, in its performance of this Agreement (including, without limitation, the performance of any and all AMVAC Development Work), AMVAC does not infringe any third party patent which blocks
either the [*] Patent or any BASF Patent (each such third party patent, a “Blocking Patent”) and, for the avoidance of doubt, the Parties agree that BASF’s obligations under Section 8.2(i) and (ii) do not mitigate the foregoing
obligation of AMVAC with respect to Blocking Patents. Accordingly, BASF’s obligations under Section 8.2(i) and (ii) shall not apply to any Costs incurred, assessed or sustained by or against any AMVAC Indemnitee as a result of alleged or actual
infringement of any Blocking Patent. 
  
 8.6 [*]
Patent. Without prejudice to any other right or remedy AMVAC may have under this Agreement or otherwise and notwithstanding the provisions of Section 8.5(A), BASF shall indemnify, defend and hold harmless any and all AMVAC Indemnitees from
and against all Costs incurred, assessed or sustained by or against such AMVAC Indemnitee(s) as a direct result of a [*] Infringement Claim(s) (as hereinafter defined) that is filed or brought by [*] against such AMVAC Indemnitee(s) (i) in a US
state or federal court or (ii) via other legal or judicial process in the US. BASF and AMVAC acknowledge and agree that the “Costs incurred, assessed or sustained by or against [an] AMVAC Indemnitee(s)” to which this
Section 8.6 refers may include general, incidental, indirect, special, punitive or consequential damages and/or lost profits of [*] but not any general, incidental, indirect, special, punitive or consequential damages and/or lost profits of any
AMVAC Indemnitee. For purposes of this Section 8.6, 

  

 Page 20 of 30 

 
“[*] Infringement Claim” means a claim(s), demand(s), suit(s), or action(s) that alleges that the exercise by AMVAC of its rights under
Sections 2.1(A)(i) or 2.1(B)(i) of this Agreement infringe the [*] Patent. The Parties hereby agree that BASF shall have no obligation to indemnify, defend or hold harmless any AMVAC Indemnitee under this Section 8.6 for any [*] Infringement Claim
if the conduct by AMVAC which is the subject of such [*] Infringement Claim is not in accordance with the terms and conditions of this Agreement. 
  
 8.7 Survival. This Article VIII shall survive the early termination or expiration of this Agreement for a period of [*]. 
  
 ARTICLE IX 
 CONFIDENTIALITY 
  
 9.1 Obligations of Non-Disclosure and Restricted Use. During the Term and for a period of [*] years thereafter [*] or until such time as [*], whichever occurs later, each of the Parties agrees to not disclose
to any Person (other than Representatives (as that term is defined in Section 9.3)) and to not use, other than for the exclusive purpose of exercising its rights and performing its obligations under this Agreement, any Confidential Information (as
that term is hereinafter defined) of the other Party; provided, however, that, subject to the provisions of Section 9.2, such obligations of non-disclosure and restricted use shall not apply to Confidential Information which:

  
 (i) the receiving Party can establish by
competent proof was already in its possession, without obligation of secrecy, and not acquired directly from the disclosing Party or any of its Affiliates; 
  
 (ii) at or subsequent to the time of disclosure, is or becomes part of the public knowledge through no breach of this Agreement by the
receiving Party or any Representative thereof; 
  
 (iii) at or subsequent to the time of disclosure, is the subject of another agreement between the Parties which permits use and disclosure; 
  
 (iv) the receiving Party may receive from a Person (other than an Affiliate of the disclosing Party), having a bona fide
right to disclose the Confidential Information in question, without restriction on disclosure and use; or 
  
 (v) is required by law or judicial process to be disclosed by the receiving Party, provided, however, that such receiving
Party shall notify the disclosing Party in as much advance time as reasonably possible of any such disclosure in order to enable such disclosing Party to take any appropriate action it sees fit under the circumstances and, provided,
further, that if requested by the disclosing Party, the receiving Party shall, at the disclosing Party’s cost and expense, use all commercially reasonable efforts to seek confidential treatment of the Confidential Information in
question, to the fullest extent permitted under Applicable Laws. 
  
 For purposes of this Article IX, “Confidential Information” means the BASF Confidential Information and the AMVAC Confidential Information. 
  
 9.2 Exceptions. Specific Confidential Information shall not be deemed to be within any of the Section 9.1 exceptions
merely because it is embraced by general disclosures within any such exception. In addition, any combination of features received as specific Confidential Information shall not be deemed to be within any of the foregoing exceptions merely because
individual features are separately within any exception but only if the combination itself, and its principle of operation, is within any such exception. The Parties acknowledge and agree that (i) any and all submissions to a Governmental Authority
in the Territory including, without limitation, the EPA and PMRA in connection with any Registration and (ii) the granting of any Registration shall not be deemed “public knowledge” within the meaning of Section 9.1(ii) or “required
by law or judicial process to be disclosed by the receiving Party” within the meaning of Section 9.1(v). 
  

 Page 21 of 30 

 9.3 Affiliates. Each Party represents and warrants that its obligations under Sections 9.1 and 9.2
shall be binding upon each of its employees, [*] (subject to the proviso at the end of this sentence), and Affiliates (for purposes of this Article IX, each being a “Representative”) who have access to any Confidential Information
of the other Party and, unless each Party has done so already, it shall do all things necessary in order to so bind each such Representative; provided, however, that any and all disclosures to [*] by BASF shall be for the limited
purposes of BASF exercising its rights under Section 2.4(C)(iii) in [*] only. Each Party shall limit access to Confidential Information of the other Party by such receiving Party’s Representatives on a strict, “need-to-know” basis.

  
 9.4 Publications and Presentations. Neither Party shall
disclose, directly or indirectly, to any Person (other than each Party’s respective Representatives, attorneys, accountants, banks and other professional advisors) the existence, or the terms and conditions. of this Agreement; provided,
however, that a Party may make such public disclosure it believes in good faith is required by Applicable Law or any listing or trading standards concerning its or its Affiliates publicly-traded securities (in which case the disclosing Party
will advise the other Party prior to making the disclosure). It is acknowledged that upon and after the Effective Date, American Vanguard Corporation, AMVAC’s parent company, will be required by Applicable Law to issue a press release and make
appropriate disclosures in its filings with the US Securities and Exchange Commission, including the filing of this Agreement as an exhibit to its annual reports; provided, however, that with respect to all such filings and other
public disclosures, this Agreement shall be redacted to the fullest extent permitted by Applicable Law. All press releases will be furnished to BASF for its review and comments prior to issuance. The Parties recognize that it may be desirable for
each of them to disclose, publish, or present publicly Confidential Information of the other Party including, without limitation, studies and data which form a part of the other Party’s Confidential Information. Each Party shall have the right
to disclose, publish, and publicly present Confidential Information of the other Party provided that it receives the express, prior written permission of such other Party to do so. All requests by one Party to the other Party regarding the
right to disclose, publish, or present publicly any Confidential Information of such other Party shall be made in writing in accordance with the provisions of Section 13.3. 
  
 9.5 Survival. Each Party agrees to limit its use and disclosure of the Confidential Information of the other Party
pursuant to the terms and conditions of this Agreement and the Confidentiality Agreement, and with respect to any inconsistency or ambiguity created thereby, the more stringent, in favor of BASF, of such agreements shall control. This Article IX
shall survive the early termination or expiration of this Agreement for a period of [*] years or until such time as [*], whichever occurs later. 
  
 ARTICLE X 
 TERM AND TERMINATION

  
 10.1 Term of the Agreement. 

 
 A. Enforceability. Each Party agrees that this
Agreement shall not be enforceable by or against either Party until the Effective Date. 
  
 B. Duration. Unless earlier terminated as provided in Section 10.2, the term of this Agreement shall commence on the Effective Date
and expire [*] (the “Term”). The “Initial Term” refers to that period commencing on the Effective Date and expiring on the last day of the [*] Contract Year following the Contract Year during which Commercialization
occurs or [*], whichever occurs earlier, and the “Extended Term” refers to the period commencing upon the day after the date on which the Initial Term expires and expiring concurrently with the Term. 
  
 C. Notification. Not later than [*] prior to
expiration of the [*], AMVAC will notify BASF whether or not AMVAC plans to Market (as that term is defined in Section 10.1.1(e) of Schedule 10.1) [*] (as that term is defined in [*]) as its [*] in the Territory during the [*] (the “AMVAC
Notification”); provided, however, that if the AMVAC Notification states that AMVAC plans to Market [*] as its [*] in the Territory during the [*] but AMVAC subsequently decides to offer to sell, promote, sell, and/or 

  

 Page 22 of 30 

 
distribute any [*] (as that term is defined in [*]) in the Territory during the [*], whether any or all of the foregoing be accomplished by AMVAC directly or
indirectly and whether the [*] is in addition to or instead of [*], AMVAC shall notify BASF no later than [*] prior to Marketing any such [*] (a “Subsequent AMVAC Notification”). For the period commencing [*] prior to expiration of
the [*] and for the remainder of the Term, BASF shall have the right to notify AMVAC, upon not less than [*] prior written notice, that BASF has received a Registration(s) for and will Market, or has granted a license to any Person who will Market,
a [*] (as that term is defined in [*]) in the Field in the Territory during the [*] (the “BASF Notification”). 
  
 D. Amendments upon Commencement of the Extended Term. Until such time as BASF provides the BASF Notification to AMVAC, and provided
that the AMVAC Notification states that AMVAC plans to Market [*] as its [*] in the Territory during the [*] and until such time as there is a Subsequent AMVAC Notification, if any, the Parties’ rights and obligations under this Agreement will
remain in full force and effect for the remainder of the Term without modification except as hereinafter provided: 
  
 (i) [*]. Effective as of the commencement date of the [*] and notwithstanding the provisions of Section 13.7, BASF’s
obligations under [*] with respect to [*] shall cease and no further [*] shall be due to AMVAC therefor. Accordingly, upon expiration of the [*], the licenses in question shall be [*] and BASF shall become a [*] thereof effective as of the
commencement date of the [*] and AMVAC shall execute promptly all such documents as are reasonably required under Applicable Law to vest in BASF its ownership interest, rights, and title in and to the [*]. 
  
 (ii) Commercialization Rights. Effective as of
the commencement date of the [*] and notwithstanding the provisions of Section 13.7, Sections 2.1(B) and 4.1 will be amended automatically as follows without the requirement of any further act by either Party: 
  
 B. Commercialization. Effective for the duration
of the [*] and subject to the terms and conditions of this Agreement, BASF grants to AMVAC a (i) [*] sublicense, without the right to grant a sublicense to any Person, under the [*] Patent and (ii) [*] license, without the right to grant a
sublicense to any Person, to use and Cite to the BASF Know-How, Information and Data and under the BASF Patents for the [*] purpose of AMVAC offering for sale, selling, promoting, and distributing Products in the Field in the Territory only.

  
 4.1 Commercialization
Rights. Pursuant to Section 2.1(B) and subject to the terms and conditions of this Agreement, AMVAC shall have a [*] right to offer for sale, sell, promote, and distribute the Compound TGAI and Products in the Field in the
Territory for the duration of the [*]. 
  
 E.
Amendments as a Result of the AMVAC Notification, Subsequent AMVAC Notification, and BASF Notification. In addition to and not in lieu of the amendments to the Agreement described in Section 10.1(D) above: if (i) the AMVAC Notification or a
Subsequent AMVAC Notification states that AMVAC plans to Market in the Territory during the [*], the Parties’ rights and obligations under this Agreement as of the date of the AMVAC Notification or Subsequent AMVAC Notification, as the case may
be, will be modified by the applicable provisions of Schedule 10.1, with such modifications being effective for the period commencing on [*], as the case may be, and expiring concurrently with expiration of the Term (the “[*]”); (ii) if
BASF provides the BASF Notification to AMVAC, and provided that the AMVAC Notification stated that AMVAC plans to Market [*] in the Territory during the [*], then until such time as there is a Subsequent AMVAC Notification, if any, the Parties’
rights and obligations under this Agreement as of the date of the BASF Notification will remain in full force and effect for the remainder of the Term, except as modified by the provisions of Schedule 10.1 with such modifications being effective for
the [*] (except that if the BASF Notification is issued prior to expiration of the [*] the Parties rights and obligations shall first be modified in accordance with the provisions of Section 10.1(D) above); and (iii) if BASF provides the BASF
Notification to AMVAC and thereafter a Subsequent AMVAC Notification states that AMVAC plans to Market [*] in the Territory during the [*], the Parties’ rights and obligations under this Agreement as of the date of the Subsequent AMVAC
Notification will be modified by the applicable provisions of Schedule 10.1, with such modifications being effective for the [*]. 
  

 Page 23 of 30 

 10.2 Termination. 
  
 A. Breach; Insolvency; Bankruptcy. In the event that either Party materially breaches this Agreement
or becomes insolvent, enters bankruptcy, receivership or other like proceeding (voluntary or involuntary) or makes an assignment for the benefit of creditors (such Party, a “Triggering Party” and each such event, a
“Default”) at any time during the Term, the other Party shall have the right to terminate this Agreement (in addition to and not in lieu of any other rights or remedies such Party may have hereunder or at law) if such Party notifies
the Triggering Party in writing of the Default in question and such Default is not cured by the Triggering Party within [*] of its receipt of notification thereof. For the avoidance of doubt, the Parties agree that a withdrawal of any Registration
for Compound TGAI or any Product undertaken by EPA or PMRA as a result, directly or indirectly, of any act or omission of AMVAC (including, without limitation, failure by AMVAC to conduct any AIRW or New Study) constitutes a material breach of this
Agreement. 
  
 B. Adverse Regulatory Action by
any Governmental Authority; Unforeseen Infringement; [*]. 
  
 (i) AMVAC’s Rights. Without prejudice to any other right or remedy AMVAC may have under this Agreement or otherwise, AMVAC shall have the right to terminate this Agreement immediately and without
penalty if: 
  
 (a) the EPA or PMRA withdraws
all Registrations for all Products for any reason; 
  
 (b) Compound TGAI poses unacceptable safety risks during formulation, transportation or other handling or to users thereof or to the environment, as such risks are determined either by any Governmental Authority in the Territory or by AMVAC
consistent with its Responsible Care® practices; or 
  
 (c) any claim that the (1) export, importation,
development, manufacture, formulation, use, promotion, offer for sale, sale and/or distribution of Compound TGAI as contemplated by the Parties in this Agreement, (2) use of any BASF Know-How, Information and Data as contemplated by the Parties in
this Agreement, or (3) performance by AMVAC under any BASF Patent as contemplated by the Parties in this Agreement, either independently or in combination (provided that if in combination, the Compound TGAI, any BASF Know-How, Information and Data,
or any BASF Patent by itself), infringes or violates any patent, trademark, trade name, trade dress, trade secret or other proprietary right of any Person. 
  
 (ii) BASF’s Rights. Without prejudice to any other right or remedy BASF may have under this Agreement or otherwise,
BASF shall have the right to terminate this Agreement immediately and without penalty if: 
  
 (a) any Governmental Agency which regulates the Compound takes any action that is not based, directly or indirectly, on any act or
omission of BASF, the result of which is to prohibit or materially restrict the export, importation, development, manufacture, formulation, use, promotion, offer for sale, sale or distribution thereof in the Territory, [*], and/or any country
wherein BASF manufactures, or has manufactured, Compound TGAI; 
  
 (b) Compound TGAI poses unacceptable safety risks during manufacture, formulation, transportation or other handling or to users thereof or to the environment, as such risks are determined either by any Governmental
Authority or by BASF consistent with its Responsible Care® practices; 
  
 (c) any claim that the (1) export, importation,
development, manufacture, formulation, use, promotion, offer for sale, sale and/or distribution of Compound TGAI contemplated by 

  

 Page 24 of 30 

 
the Parties in this Agreement, (2) use of any BASF Know-How, Information and Data as contemplated by the Parties in this Agreement, or (3) performance by
AMVAC under any BASF Patent as contemplated by the Parties in this Agreement, either independently or in combination (provided that if in combination, the Compound TGAI, any BASF Know-How, Information and Data, or any BASF Patent by itself),
infringes or violates any patent, trademark, trade name, trade dress, trade secret or other proprietary right of any Person; or 
  
 (d) BASF decides to cease all sales of Compound TGAI and products containing either such Compound TGAI or other Compound technical form
of active ingredient as an active ingredient [*]. 
  
 C. Mutual Agreement. If the Parties mutually agree in writing to terminate this Agreement prior to the natural expiration thereof, the effect(s) thereof shall be as if the Agreement expired in accordance with its terms. 

 
 10.3 Effects of Expiration and Termination. 
  
 A. Expiration. Subject to the provisions of Schedule
10.1, upon expiration of the Term (i) AMVAC and BASF will [*] all Additional Data and Additional Initial Registration Work Data and BASF will not be obligated to pay AMVAC any further [*] therefor and (ii) the licenses granted to AMVAC under Section
2.1 will be [*] and such licenses will [*]. 
  
 B. Breach; Insolvency; Bankruptcy. In the event that this Agreement is terminated pursuant to [*] is the Triggering Party then: (i) [*] shall assign all of its rights and interest in and to all [*] or its designee; (ii) all licenses
granted under this Agreement by [*] shall survive; and (iii) all licenses granted under this Agreement by [*] shall terminate concurrently with the effective date of termination of this Agreement. In the event that this Agreement is terminated
pursuant to [*] is the Triggering Party then: (i) all licenses granted under this Agreement by [*] shall survive provided, however, that in the event that the license granted to [*] upon termination of this Agreement, such license
shall be amended without the need for any further action by either Party, notwithstanding the provisions of Section 13.7, to be [*] effective as of [*] and (ii) all licenses granted under this Agreement by [*] shall terminate concurrently with the
effective date of termination of this Agreement except that the license granted by [*] to be mutually agreed and the license granted under [*] shall survive. 
  

C. Regulatory Action by any Governmental Authority; Unforeseen Infringement; [*]. Subject to the provisos at the end of this
sentence, if this Agreement is terminated by [*] pursuant to [*] or by [*] pursuant to [*] all licenses granted by one Party to the other under this Agreement shall [*] concurrently with the effective date of termination of this Agreement;
provided, however, that if this Agreement is terminated by [*] pursuant to [*], the provisions of Article XII shall apply if applicable and, provided, further, that if this Agreement is terminated by [*] pursuant to [*]
shall assign all of its rights and interest in and to all [*] or its designee. 
  
 D. Return of Information. Upon the early termination or expiration of this Agreement, AMVAC shall return to BASF all BASF Know-How,
Information and Data; provided, however, that if this Agreement is terminated for breach by BASF or if the license(s) granted to AMVAC survive the expiration or termination of this Agreement, AMVAC shall be entitled to retain for the
duration of the license(s) that survive any such termination or expiration that BASF Know-How, Information and Data necessary to enable AMVAC to exercise the rights granted under such license(s). 
  
 E. Sale of Inventory. Upon the early
termination or expiration of this Agreement, AMVAC shall have the right, at its sole discretion but in accordance with the terms and conditions of this Agreement including, without limitation, Section 2.1 and Article V, to sell its inventory of
Compound TGAI and Products. BASF shall have the right to purchase such inventory at [*]; provided, however, that if BASF purchases such inventory it will not be entitled to any [*] as provided in [*] with respect to such sale by AMVAC.

  

 Page 25 of 30 

 ARTICLE XI 
 FORCE MAJEURE 
  
 The performance of any obligation hereunder may be reduced or suspended by either Party, in whole or in part, without liability, by promptly notifying the other Party of the nature and estimated duration of the suspension period in the
event of: any act of God, earthquake, war, terrorism, riot, fire, explosion, accident, flood, sabotage; lack of adequate fuel, power, raw materials, labor, containers or transportation facilities; compliance with any Governmental Authority,
Applicable Law or national defense requirement or any event beyond the reasonable control of the notifying Party, which event makes impracticable performance of the obligation in question. 
  
 ARTICLE XII 
 [*] OFFER 
  
 If at any time during the Term BASF decides to cease [*] of Compound TGAI and products containing either such Compound TGAI or other Compound technical form of active ingredient as an active ingredient globally (for
purposes of this Agreement only and subject to the proviso at the end of this sentence, the “Compound Business”) and to sell the Compound Business (subject to the proviso at the end of this sentence, a “[*]”) and elects to
[*] this Agreement pursuant to [*], BASF shall provide written notice thereof to AMVAC (the “[*] Notice”); provided, however, that the Parties acknowledge, understand, and agree that the composition of assets and
intangibles, if any, comprising the “Compound Business” is at the sole and exclusive discretion of BASF and its Affiliates; and, provided, further, that a [*] shall be deemed to mean only a [*] from the Compound Business.
BASF’s obligations under this Article XII shall only be triggered in the event of a decision by BASF to [*] the Compound Business and, by way of example and not limitation, such obligations shall not be triggered if BASF decides to [*], its
entire herbicide crop protection portfolio, or its entire crop protection business. Upon receipt of the [*] Notice, AMVAC shall have the [*], but not the obligation, to offer to purchase such Compound Business by providing a sufficiently detailed
written notice of AMVAC’s offer to BASF in accordance with the terms and conditions of the [*] Notice. This Article XII shall not be construed as precluding BASF from either [*] any Person’s offer in connection with the Compound Business,
a [*], or otherwise; provided, however, that in the event that BASF receives any such offer it shall advise AMVAC thereof and AMVAC shall have the right to submit an offer or, in the case of a [*], a second offer. If in the reasonable
opinion of BASF the [*] received from AMVAC and any Person are equivalent in all material respects, BASF shall [*] with AMVAC with respect to acquisition of the Compound Business. 
  
 ARTICLE XIII 
 MISCELLANEOUS 
  
 13.1 Applicable
Laws. Each of the Parties agrees to comply with all Applicable Laws with respect to the performance of their obligations hereunder. 
  
 13.2 Relationship of the Parties. During the Term, BASF and AMVAC shall act as independent contractors and nothing herein shall be construed so as
to constitute BASF or AMVAC as being a partner, joint venturer, agent or representative of the other for any purpose whatsoever. Neither BASF nor AMVAC shall engage in any conduct which might create the impression or inference that the other Party
is a partner, joint venture, agent or representative thereof. Each of BASF and AMVAC shall be solely responsible for the discharge of its respective obligations and liabilities to Persons and shall have no right to indemnity or contribution from the
other Party in respect therefor except insofar as expressly provided in Article VIII. 
  
 13.3 Notice. All notices and reports required under, and other communications with respect to, this Agreement shall be in writing, in the English language, and given or sent to the Party to be notified at the
addresses set forth below either personally and thereby deemed to be given on that day, or by facsimile transmission and thereby deemed to be given on the day following or by registered letter and thereby deemed to be given on the third day
following the day of posting. 
  

 Page 26 of 30 

 If to BASF: 
  
 BASF Corporation 
 26 Davis Drive 

Research Triangle Park, NC 27709-3528 
 Attn: Director, Global Strategic Marketing, Herbicides 
 Fax: 919-547-2476 
  
 with a copy to the following in the event of notices of material breach
including, without limitation, notices threatening termination of this Agreement: 
  
 BASF Corporation 
 100 Campus Drive 
 Florham Park, New Jersey 07932 
 Attn:
Counsel, Agricultural Products Division 
 Fax: 973-245-6702 
  
 If to AMVAC: 
  
 AMVAC Chemical Corporation 
 4694 MacArthur
Court 
 Suite 1250 
 Newport
Beach, CA 92660 
 Attn: President 
 Fax: (949) 260-1201 
  
 with a copy to the following in
the event of notices of material breach including, without limitation, notices threatening termination of this Agreement: 
  
 McDermott Will & Emery LLP 
 18191 Von
Karman Avenue, Suite 400 
 Irvine, CA 92612 
 Attn: John B. Miles, Esq. 
 Fax: (949) 851-9348 
  
 13.4 Non-Waiver. Any waiver by either Party of a breach of any provision of this Agreement shall not operate as or be
construed to be a waiver of any other breach of that provision or of any breach of any other provision of this Agreement. The failure of either Party to insist upon strict adherence to any term or condition of this Agreement on one or more occasions
will not be considered a waiver or deprive that Party of the right thereafter to insist upon strict adherence to that term or condition or any other term or condition of this Agreement. Any waiver must be in writing and signed by the Party against
whom enforcement is sought. 
  
 13.5 Assignment. This
Agreement shall [*] by either Party [*] of the other Party; [*] assign this Agreement to any of its Affiliates and, subject to the provisions of Article XII, to any successor in interest to BASF’s business which is the subject matter of this
Agreement [*] 
  
 13.6 Binding Effect. This Agreement shall
be binding on the Parties and their Affiliates as well as their respective successors and permitted assignees. 
  
 13.7 Amendment. Except as expressly provided in this Agreement, amendments to this Agreement must be in writing, signed by both Parties and include
an affirmative statement that this Agreement is being amended thereby. 
  
 13.8 Severability. If any term of this Agreement shall be found to be invalid, illegal or unenforceable, it is the intention of the Parties that the remainder of this Agreement shall not be affected thereby; 

  

 Page 27 of 30 

 
provided, however, that neither Party’s rights under this Agreement have been materially adversely affected. It is further the intention
of the Parties that in lieu of each such provision which is invalid, illegal or enforceable, there be substituted or added as part of this Agreement a provision which shall be as similar as possible in the economic and business objectives intended
by the Parties to such invalid, illegal or unenforceable provision, but which shall be valid, legal and enforceable. 
  
 13.9 Headings. The headings contained in this Agreement are for convenience of reference only, are not considered a part of this Agreement and
shall in no way affect or alter the meaning or effect of any of the provisions of this Agreement. 
  
 13.10 Counterparts. This Agreement may be executed simultaneously in one (1) or more counterparts, each of which shall be deemed to be an original,
but all of which shall constitute one and the same instrument. 
  
 13.11 Governing Law. This Agreement shall be governed by and construed in accordance with the laws of [*] without regard to its conflict of laws rules or principles. 
  
 13.12 Entire Agreement. No term, condition or other provision
set forth in the LOI or the Confidentiality Agreement, or in any attachment, addendum or schedule to this Agreement, shall supersede any term, condition or other provision of Articles I through XIII of this Agreement and, with respect to any
inconsistency or ambiguity created thereby, Articles I through XIII of this Agreement shall control. This Agreement, together with Schedules [*] sets forth the entire agreement and understanding between the Parties with respect to the subject matter
hereof and hereby supersedes all prior discussions, negotiations and agreements, whether oral or written, among them with respect to the same including, without limitation, the LOI and the Confidentiality Agreement. In accordance with the provisions
of [*] of the LOI, the Parties agree that the LOI and therefore the [*] expire as of the Effective Date. 
  
 13.13 Prevailing Language. This English version of this Agreement, regardless of whether a translation in any other language is or shall be
made, shall be the only authentic one. 
  
 IN WITNESS WHEREOF,
the Parties hereby have caused this Agreement to be signed by their duly authorized officers on the dates set forth below. 
  

							
	BASF AKTIENGESELLSCHAFT	 	AMVAC CHEMICAL CORPORATION
		
	  

	 	  

	 Name:
	 	 	 	 Name:
	 	 Glen Johnson

	 Title:
	 	 	 	 Title:
	 	 
	 Date:
	 	 	 	 Date:
	 	 

  

			
	BASF AKTIENGESELLSCHAFT
	
	  

	 Name:
	 	 
	 Title:
	 	 
	 Date:
	 	 

  

 Page 28 of 30 

 SCHEDULE 1.1 
  
 DATA DEPRECIATION FORMULA 
  
 [*] 
  
 DATA COMPENSATION FORMULA 
  
 [*] 

 SCHEDULE 1.2 
 ADDITIONAL DEVELOPMENT WORK 
  
 See AMVAC’S Microsoft Excel file “[*]”, updated [*], incorporated herein by this reference1 

	1	The Excel spreadsheet has been omitted. 

 SCHEDULE 1.10 
 BASF KNOW-HOW, INFORMATION AND DATA 
  
 See that BASF formulation know-how and information with respect to Compound TGAI, any BASF Product, and/or the Solo Product, other than BASF Study Data, contained on the [*], incorporated herein by this reference

 SCHEDULE 1.11 
 BASF PATENTS 
  
 US
[*] 
 CA [*] 
  
 US Ser. No. [*] 
 CA [*] 
  
 US [*] 
 US Ser. No. [*] 
 CA [*] 
  
  

 SCHEDULE 1.13 
 BASF STUDY DATA 
  
 See Schedule [*] of the LOI, incorporated herein by this reference 

 SCHEDULE 1.16 
 COMPOUND CHEMICAL NAME AND STRUCTURAL FORMULA 
  
 [*] 

 SCHEDULE 1.44 
 SPECIFICATIONS 
  
 Compound TGAI specifications to be provided by BASF with each delivery to AMVAC thereof 
  
 Solo Product specifications to be provided by BASF with each delivery to AMVAC thereof 

 SCHEDULE 2.7 
 BASF EMPLOYEES WHO WILL PROVIDE ASSISTANCE TO AMVAC 
  
 From BASF: [*] 
  
 From BASF Corporation: [*]

  
 From BASF Canada: [*] 
  
  

 SCHEDULE 5.6(A) 
 SHARED GROSS PROFIT FOR [*] PRODUCTS FORMULA* 
  
 [*] 

 SCHEDULE 5.11(A) 
 METHODS OF ANALYSIS 
  
 Methods of
Analysis to be provided by BASF to AMVAC prior to initial delivery of Compound TGAI thereto 

 SCHEDULE 10.1 
 TERMS AND CONDITIONS DURING THE [*] 
  
 This Schedule 10.1 sets forth certain rights and obligations of the Parties during the [*]. For the avoidance of doubt, unless expressly stated otherwise in this Schedule 10.1, all rights and obligations of the
Parties remain in full force and effect for the duration of the Term. 
  
 10.1.1 Definitions. For purposes of this Schedule 10.1, the following capitalized terms shall have the following meanings: 
  
 a. “Compound Product” means any [*] which (i) is packaged as and offered for sale and sold in either a [*], (ii) for the
US, has at least [*] of Compound TGAI [*] use rate or such lower use rate to which BASF consents in writing, and (iii) for Canada, has at least [*] of Compound TGAI [*] use rate or such lower use rate to which BASF consents in writing. 

 
 b. “[*] Herbicide” means any [*]
herbicide formulation other than any [*]. 
  
 c.
“Different Product” means any [*] that is either (i) a [*] type, as such formulation types are defined by CropLife International in its codes for technical and formulated pesticides as published in the Manual on Development and
Use of FAO and WHO Specifications for Pesticides, First Edition, prepared by the FAO/WHO Joint Meeting on Pesticide Specifications (JMPS), Rome, 2002 (see pages 235-239), such pages attached hereto as Exhibit A, from any [*] Marketed by
AMVAC or (ii) is the [*] type as any [*] Marketed by AMVAC but uses a [*] variation in the concentration of [*] active ingredients in the [*] in question. 
  
 d. “Formulated Product” means any [*] formulation which contains Compound TGAI as an [*] ingredient. 
  
 e. “Market” means to, directly or
indirectly, offer for sale, sell, promote, and distribute . 
  
 f. “[*] Product” means any [*] that is the [*] formulation type as any [*] Marketed by AMVAC but uses [*] variation in the concentration of [*] active ingredients in the [*] in question. 

 
 10.1.2 AMVAC Markets [*] but no [*] and BASF or a Person licensed by
BASF Markets only [*]. 
  
 a. If AMVAC
notifies BASF that AMVAC will Market [*] but no [*] in the Field in the Territory during the [*] and if BASF provides a BASF Notification to AMVAC and thereafter BASF Markets [*], then the provisions set forth in Sections 10.1.2(b) and (c) below
will become effective, notwithstanding the provisions of Section 13.7 of the Agreement, for the duration of the [*]. 
  
 b. Section 5.6(A) of the Agreement will be amended automatically without the requirement of any further act by either Party as follows:

  
 A. [*] Products. In
consideration for the licenses granted in Section 2.1 to AMVAC with respect to [*] Products, for the Contract Year during which AMVAC receives the BASF Notification and each [*] Contract Year during which any [*] Product is sold
by AMVAC, BASF shall receive a [*] of the Shared Gross Profit for [*] Products. No later than [*] of the Contract Year during which AMVAC receives the BASF Notification and each [*] Contract Year, AMVAC
shall prepare and provide to BASF an interim report which reasonably estimates the expected Shared Gross Profit for [*] Products for the then-current Contract Year. AMVAC shall reconcile the Shared Gross Profit for [*] Products for the
Contract Year in question and remit to BASF [*] via wire transfer to an account specified by BASF no later than [*] of the Contract Year during which the sales of the [*] Products leading to the Shared Gross Profit for
[*] Products in question were made, such earnings to be determined by AMVAC in accordance with generally accepted accounting principles for the US. For purposes of this Agreement, “Shared Gross Profit for [*]
Products” for any given Contract Year means [*]. 

 B. [*] Products. In consideration for the licenses granted
in Section 2.1 to AMVAC with respect to [*] Products, for the Contract Year during which AMVAC receives the BASF Notification and each [*] Contract Year during which any [*] Product is sold by AMVAC, it shall pay to BASF (i) a
royalty in an amount equal to [*] contained, in the aggregate, in the [*] Products sold by AMVAC in the US during the Contract Year in question (the “US Royalty”) and (ii) a royalty in an
amount equal to [*] contained, in the aggregate, in the [*] Products sold by AMVAC in Canada during the Contract Year in question (the “Canadian Royalty” and, together with the US Royalty,
the “[*] Products Royalty”). No later than each [*] of the Contract Year during which AMVAC receives the BASF Notification and each [*] Contract Year, AMVAC shall prepare and provide to BASF an
interim report which reasonably estimates the expected [*] Products Royalty for the then-current Contract Year. AMVAC shall reconcile the [*] Products Royalty for the Contract Year in question and remit to BASF payment therefor in
[*] via wire transfer to an account specified by BASF no later than [*] of the Contract Year during which the sales of the [*] Products leading to the [*] Products Royalty payment in question were made, such earnings to be
determined by AMVAC in accordance with generally accepted accounting principles for the US. 
  
 c. In consideration of the licenses granted to BASF pursuant to Sections 2.4(C)(i) and (ii) of the Agreement with respect to New Study
Data, BASF’s obligations under Section 2.4(C)(iv) of the Agreement shall cease effective on the date of the BASF Notification and BASF shall compensate AMVAC in accordance with the provisions of the Data Compensation Formula covering the
circumstances described in Section 10.1.2(a) above. 
  
 10.1.3 AMVAC Markets [*] but no [*] and BASF or a Person licensed by BASF Markets any [*]. 
  
 a. If AMVAC notifies BASF that AMVAC will Market [*] but no [*] in the Field in the Territory during the [*] and if BASF provides a BASF
Notification to AMVAC and thereafter BASF Markets any [*], then the provisions set forth in Sections 10.1.3(b), (c), and (d) below will become effective, notwithstanding the provisions of Section 13.7 of the Agreement, for the duration of the [*].

  
 b. Sections 5.5(B) and (C) of the Agreement
will be amended automatically without the requirement of any further act by either Party as follows: 
  
 B. [*] Contract Years Following the Contract Year During Which Commercialization Occurs When AMVAC’s Orders Equal or
Exceed the Minimum Volume. For purposes of this Section 5.5(B) and Section 5.5(C), “Minimum Volume” means [*] of one hundred percent (100%) Compound TGAI. Provided that in the [*]
Contract Year following the Contract Year during which Commercialization occurs AMVAC orders an amount of Compound TGAI which is equal to or exceeds the Minimum Volume, the Compound Price shall be equal to [*]. 
  
 C. [*] Contract Years Following the Contract Year
During Which Commercialization Occurs When AMVAC Orders Less than the Minimum Volume. If in the [*] Contract Year following the Contract Year during which Commercialization occurs AMVAC orders an amount of Compound TGAI which is less than
the Minimum Volume, the Compound Price for such year shall be equal to [*]. 
  
 c. [*] of the Agreement, all references to the [*] in the Agreement including, without limitation, [*] thereof, and [*] of the Agreement
will be deleted in their entirety without the requirement of any further act by either Party. Accordingly, BASF will not be entitled to any [*] for the duration of the [*]. 
  
 d. In consideration of the licenses granted to BASF pursuant to Sections 2.4(C)(i) and (ii) of the Agreement
with respect to New Study Data, BASF’s obligations under Section 2.4(C)(iv) of the Agreement shall cease effective on the date of the BASF Notification and BASF shall compensate AMVAC in accordance with the provisions of the Data Compensation
Formula covering the circumstances described in Section 10.1.3(a) above. 

 10.1.4 AMVAC Markets [*] in addition to any [*] and BASF or a Person licensed by BASF Markets
[*]. 
  
 a. If AMVAC notifies BASF
that AMVAC will Market [*] in addition to or instead of any [*] in the Field in the Territory during the [*] and if BASF provides a BASF Notification to AMVAC and thereafter BASF Markets [*], then the provisions set forth in Sections 10.1.4(b) and
(c) below will become effective, notwithstanding the provisions of Section 13.7 of the Agreement, for the duration of the [*]. 
  
 b. [*] of the Agreement, all references to the [*] in the Agreement including, without limitation, [*] thereof, and [*] of the Agreement
will be deleted in their entirety without the requirement of any further act by either Party. Accordingly, BASF will not be entitled to any [*] for the duration of the [*]. 
  
 c. In consideration of the licenses granted to BASF pursuant to Sections 2.4(C)(i) and (ii) of the Agreement
with respect to New Study Data, BASF’s obligations under Section 2.4(C)(iv) of the Agreement shall cease effective on the date of the BASF Notification and BASF shall compensate AMVAC in accordance with the provisions of the Data Compensation
Formula covering the circumstances described in Section 10.1.4(a) above. 
  
 10.1.5 AMVAC Markets [*] in addition to [*] and BASF or a Person licensed by BASF Markets [*]. 
  
 a. If AMVAC notifies BASF that AMVAC will Market [*] in addition to or instead of [*] in the Field in the Territory during the [*] and if
BASF provides a BASF Notification to AMVAC and thereafter BASF Markets [*], then the provisions set forth in Section 10.1.5(b) below will become effective, notwithstanding the provisions of Section 13.7 of the Agreement, for the duration of the [*].

  
 b. In consideration of the licenses granted
to BASF pursuant to [*] of the Agreement with respect to [*], BASF agrees to pay to AMVAC as follows: 
  
 (1) Subject to the provisions of clause (2) immediately below, BASF’s obligations under [*] of the Agreement for [*] shall cease
effective on the date of the BASF Notification and no further [*] to AMVAC therefor. Accordingly, the licenses in question shall then be [*] and BASF would become a [*] effective as of the date of the BASF Notification and such [*] shall become [*].
AMVAC shall execute promptly all such documents as are reasonably required under Applicable Law to vest in BASF [*]. 
  
 (2) If under the circumstances described in Section 10.1.5(a) above BASF has granted any Person a license to Market [*] in the Field in
the Territory, then BASF’s obligations under [*] of the Agreement shall cease effective on the date of the BASF Notification and BASF shall compensate AMVAC for [*] in accordance with the provisions of the [*] covering the circumstances
described in Section 10.1.5(a) above. 

 EXHIBIT A 
 TO SCHEDULE 10.1 
  
 Pages 235-239 of Manual on Development and Use of FAO and WHO Specifications for Pesticides, 
 First Edition, prepared by the FAO/WHO Joint Meeting on Pesticide Specifications (JMPS), Rome, 2002

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00084-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00084-of-00352.parquet"}]]